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Introduction:
The association between HIV and renal dysfunction is well documented in the
HIV literature (Wyatt & Klotman 2006, Gupta et al. 2005 as cited by Mocroft et al.
2007). A syndemic relationship can exist between these two serious health
conditions (Singer 2009). While adherence to HIV medications is important, it
can be difficult for a person who suffers from co-morbidity. In this thesis I
examine possible barriers to adherence for HIV+ patients placed on renal dosing
regimens. The data for this research came from a larger psychological study on
medication adherence. Of the 590 patients in the study, 12 patients had their
HIV medications changed to a renal dosed regimen. All 12 patients suffered
from renal toxicity from the ARV medication, Tenofovir. The purpose of this
thesis is to identify whether there are specific barriers to adherence that the
patients on renal dosing identified and those on normal dosing schedules did not.
The hypothesis of this thesis is that the switch to a renal dosed regimen will
increase the barriers and difficulties patients have in adhering to their ARV
medications.
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This thesis begins with an examination of the literature on HIV and renal
dysfunction, paying special attention to renal failure due to nephrotoxicity.
Nephrotoxicity is the toxic effect that some medications have on the kidneys.
Then, this thesis looks at participants’ responses to a survey that measured ARV
medication adherence. From this data, this thesis analyzes and discusses
findings to determine if any trends exist between specific groups of participants.
The data for this thesis came from a longitudinal, psychological investigation of
barriers to adherence for ARV medications, called the LifeWindows Project
(Fisher et al. 2011). The research project ran from March 2006 to March 2008 at
five HIV clinics located in the state of Connecticut. Participants could only
participate if they were patients of the clinic. Patients participated in the study for
18 months and could complete a survey only once per month.
I worked on this study as a research assistant. While I was not involved in the
design of the study, my duties included the retention of participants and
maintenance of participant information. During the study, I noticed that some
patients had their medication regimens changed from taking the medications
every day, to only taking the medications once or twice a week. This was
strange because ARV regimens require patients to take the medications
everyday in order to be effective. After investigating this occurrence the team
found the medication, Viread, caused kidney problems in some of the patients.
With the kidneys unable to function, these patients needed to undergo dialysis
treatments. Due to the way the body excreted the medication from the kidneys,
the patients had to lower their ARV intake or the medication would become toxic.
At the onset of the study, the medical community was unaware about the side
effects incurred from prolonged use of Viread, which includes nephrotoxicity.
Since that time, around 2% of the HIV population in the United States suffer from
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this adverse reaction (Hamzah & Post 2009). There is still more to learn about
this issue, especially if other medications can cause nephrotoxicity.
Renal dosing is a strategy a provider utilizes when a particular medication
causes nephrotoxicity. The provider lessens the number of prescribed doses in
order to minimize medication toxicity in the patient. This thesis examines the
barriers to adherence for these participants by examining their responses on
demographics and barriers to adherence. Due to the small sample size this
thesis cannot represent the greater HIV population. Instead, this thesis intends
to highlight areas that should be further investigated and tested. Learning about
the barriers that these participants faced can help future researchers focus their
efforts in addressing barriers to adherence for HIV+ patients placed on renal
dosing.
Background on HIV and ARVs
History of HIV:
In the early 1980s, the human population became acutely aware of HIV. The
virus quickly spread worldwide, and this serious health problem became a global
pandemic. To date, the virus has infected over 33 million people worldwide
(WHO: Global Summary of the HIV/AIDS epidemic, December 2008). Like many
diseases, the virus has affected developing nations the hardest. However, HIV is
still a serious problem in developed nations like the United States. To date, HIV
claimed the lives of over half a million Americans, disproportionately affecting
poor and minority populations (AVERT: HIV and AIDS statistic summary).
HIV is among the deadliest of diseases because the virus enters a host and
attacks the CD4-cells in the body. These cells are integral in the maintenance of
a healthy immune system. The CD4-cells combat infections and foreign
organisms that enter the body. The virus can alter the genetic coding of the
CD4-cells, forcing them to replicate versions of the virus instead of creating more
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CD4-cells. Over time the virus destroys the CD4-cell. With a low number of
CD4-cells in the body the host cannot fight off infections and becomes vulnerable
to opportunistic infections and diseases.
In the beginning of the HIV epidemic, HIV+ patients viewed infection as a death
sentence because providers lacked medications to combat the virus. This led to
compromised immune systems for the patients. Scientists searched for ways to
combat HIV for years before they found an effective pharmaceutical combination
-- the highly active antiretroviral therapy (HAART) -- that transformed AIDS from
a death sentence to a chronic disease (Kak et al. 2000).
Yet, the first ARV medication was not available until 1987, with the introduction of
AZT, the first FDA approved medication, for the treatment of HIV (FDA: HIV/AIDS
Historical Timeline). Since then, newer and more effective medications are used
to fight the virus. In 1996, the medical community started to combine aggressive
ARVs into medication regimens, giving rise to HAART (Moore et al. 2005). With
the effectiveness of the new medications and medication regimens, mortality
rates dropped as people lived with HIV infection (Hooshyar et al. 2007).
Although HAART is effective in battling HIV and keeping the individual alive,
there is no cure for HIV. The medications do not destroy the virus. Rather, they
keep the virus at bay by either preventing it from entering the CD4-cells or by
preventing its replication.
Adherence to Medication:
Since HAART cannot destroy the virus, an HIV+ patient is infected for life. The
patient must take the medication every day in order to keep the virus from
destroying the CD4-cells and replicating itself. The virus can mutate when a
patient misses doses of his/her medication. HIV, as a type of RNA virus,
produces high yields over short periods of times. This high replication rate
greatly increases the rate at which mutations occur. HIV can rapidly respond to
new challenges and environments, such as a missed dose of an ARV medication
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(Domingo & Holland 1997). If any of these new mutated versions of the virus
become immune to the medication, resistant strains of the virus will make
existing medications ineffective. Such drug resistance renders the particular
medication the patient took no longer effective in stopping HIV replication. If the
patient passes the mutated virus to another person, the newly infected person
will contract a drug resistant strain, making that particular medication ineffective
for both parties (Rintamakami et al. 2006, Fogarty et al. 2002).
Thus, HIV+ patients must adhere to their medication regimen in order for the
treatment to be effective. Poor adherence is the number one cause of treatment
failure for chronic diseases, especially HIV (Cressey & Lallemant 2007). A 95%
adherence rate is necessary to maintain medication efficacy and prevent the
virus from developing resistance to the medication (Bautista-Arredondo et al.
2010).
Since adherence is of the utmost importance, health care providers should be
involved in their patients’ care. The providers must also ensure that their patients
can adhere to medication regimens before prescribing HAART by observing the
patients’ medication-taking behaviors (Hawkins 2010). Adherence to HAART is
the determining factor in whether or not the therapy will be effective (Barfod et al.
2006). Unfortunately there is no way for doctors to determine which of their
patients will not adhere to HAART. Therefore, providers must understand the
barriers that cause their patients to be noncompliant, and identify and address
these barriers so that patients can adhere to their medications (Fogarty et al.
2002, Bangsberg et al. 2001).
Barriers to Adherence:
Before providers can understand the barriers to adherence they first need to
understand the process of living with HIV and how barriers develop. Some of
these factors are external and lie outside of the patient’s control. Many of these
external factors develop out of economic, social, and political issues (Bautista-
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Arredondo et al. 2010). The development of these factors is a result of HIV’s
concentration among marginalized populations such as the poor, undereducated, intravenous drug users (IDUs), people of color, and prisoners. These
groups also suffer from negative social stigma, which denies them economic
gains and political control to address issues in their lives (Rintamakami et al.
2006). Members of stigmatized groups have less access to resources and may
have a harder time obtaining medications to adhere to. Many of these patients
lack the social support structures necessary to counteract these factors
(Maskovsky 2005, Hill et al. 2003). To help these patients adhere to their
medications, researchers, doctors, and public health officials designed numerous
interventions to address these barriers and improve adherence.
Other external factors that affect medication adherence lie not with society but
with the provider. At the time that the data for this thesis was collected, all but
one of the HAART regimens included multiple HIV medications. No single
regimen works for every patient. Sometimes the doctor does not prescribe an
effective regimen or the correct dosing because medications react differently in
different people (Cressey & Lallemant 2007). The doctor may have to try several
different regimens in order to find one that will work for the patient. Each time a
change is made in a medication regimen, it increases the difficulty for the patient
to adhere to the regimen (Vrijens & Urquhart 2005).
Adherence is also affected by the relationship between the patients and their
providers. Patients that trust their doctor, and the prescribed therapy, are more
likely to be adherent (Barfod et al. 2006, Remien et al. 2003). It is not
uncommon for patients to keep information, such as their adherence, from their
providers (Hill et al. 2003). Health care providers need to gain the trust of their
patients when prescribing medications. It is vital that providers take a patientcentered approach to caring for their patients (Stein 2009). Even successful
patient-provider relationships can dissipate over time (Hunt et al. 1989).
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While there are many external factors that the patient does not have control over
there are internal factors that the patient can control. These internal factors are
associated with the beliefs a patient has, the behaviors a patient exhibits, and the
actions a patient takes. These internal factors can create adherence barriers that
can affect patients, regardless of their socio-economic status. Doctors,
researchers, and patients must identify and overcome these barriers for viral
suppression to occur (Chesney 2000). Interventions to increase patient
adherence developed from a better understanding of these barriers (Berg et al.
2004, Bogart et al. 2010). Some of these interventions use discussion and
education to change a patient’s beliefs and behaviors (Mills et al. 2006). The
provider can work with the patient and educate him/her on the medications and
on adherence techniques (Roberts 2000). Researchers also developed
interventions that patients can use at home (Jerant et al. 2005).
Even after a provider identifies the internal and external factors that affect
adherence, he/she still needs to understand the complex barriers that a patient
lives with. These barriers are broad and deal with a wide range of aspects of
living with HIV (Chesney 2000). Each patient is unique and has different
experiences, so it is difficult to determine if a given factor will cause a barrier for a
given patient. Researchers found four factors that are salient predictors of
noncompliance, which include the patient’s living situation, psychological health,
access to medications, and history of substance abuse (Fisher et al. 2006).
These factors comprise the IMB model of adherence to HAART. If a patient has
difficulties with any of these factors, barriers to adherence usually follow. This
model is linked with the individual’s health outcomes, which include his/her
physical health, quality of life, and current HIV status (Fisher et al. 2006).
Increasing Adherence: The IMB Model:
While some patients have stable living situations and access to medications, and
lack psychological issues, and substance abuse problems, these patients can
still possess barriers to adherence. Trying to identify the barriers to adherence

!

(!

for these patients is extremely difficult. One tool that is effective is the
Information, Motivation, and Belief (IMB) model of adherence (Fisher et al. 2006).
By using this model, providers can better understand, predict, and promote
adherence with their patients. With the IMB model the providers can examine
the information patients possess about HIV and their medications; the
motivations and beliefs patients have about the virus, their medications, and what
it is like to live with HIV; and the behavioral skills the patients possess and their
ability to adhere to their medications. When patients are “well informed,
motivated to act, and possess behavioral skills required to act, adherence can be
maintained” (Fisher et al. 2006). It is important to take the concept of culture into
account when looking at the factors that affect adherence. Cultural practices and
beliefs will vary, which can change the understanding of these factors. When
utilizing the IMB model of adherence one must understand the culture to
determine the model-based elements of the IMB model that are appropriate
(Fisher et al. 2006). The IMB model of adherence helps providers identify
adherence barriers for patients who may not have any of the four major factors
associated with non-adherence as discussed above.
When using the IMB model it is important for providers to remember that life with
HIV is not uniform for all people. Different groups of people will face different
issues, and as a result may have different barriers, and the barriers associated
with one group may not affect another group. For example, the barriers that
affect IDUs are quite different from those that affect other groups (Krusi et al.
2010). When researching medication adherence providers and researchers
should always look for other factors that can affect adherence. To do so the
providers and researchers need to comprehend what life is like for the patients
and understand the patients’ values, judgments, habits, and behaviors (Max &
Sherer 2000).
On the surface, adherence appears to be cut and dry. A provider wants to know
if his/her patient took the medications as prescribed. When a patient is not
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adherent to his/her medication the medical community considers the patient to be
noncompliant. The language of compliance shows the power dynamic that the
provider has over the patient (Trostle 1988). The provider is the holder of
knowledge and the patient is subject to the rituals of the healthcare setting
(Papen 2010). This noncompliant point of view is only from the doctor’s and is
devoid of the patient’s perspectives. Noncompliance can make it appear that the
patient does not take care of himself/herself, and that the patient lacks agency.
Yet, there are things that the patient can do for his/her health that do not include
HAART, which a provider may not take into account. The patient can attempt to
manage HIV in ways that are not assessed by the clinician (Trostle 1988).
Similarly, the language of noncompliance can place blame on the patient and the
provider may assume that the patient ‘disobeyed’ his/her instructions (Rousse
2010). Yet, the patient could be a victim of structural violence due to
discrimination and economic inequality (Scheper-Hughes & Bourgois 2004 as
cited by Rousse 2010, and Chapman & Berggren 2005). Thus, many in the
medical community use the language of adherence, with the hope that the power
differences will not be present in the language. “The shift from compliance to
adherence demonstrates a growing awareness of power relations in doctorpatient interactions and of the frequently cited distrust in institutions such as
biomedicine” (Leibing 2010).
One strategy that providers can use to better understand patients is to become
aware of the cultural aspects of their patients’ lives. The hope is that by
understanding their patients; providers can connect to their patients (Stein 2009).
Providers attempt to do this through cultural competency. Cultural competency
refer[s] to a body of knowledge, skills, attitudes, and behavior in which physicians
ought to be trained if they are to deliver “sensitive,” “empathetic,” “humanistic”
care that is “respectful” of patients, involves effective “patient-centered
communication,” and responds to patients’ “psychosocial issues and needs” (Fox
2005).
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Unfortunately, many providers and medical schools view cultural competency as
a list of “dos and don’ts” that correlate with a particular population (Betancourt
2004). This view of cultural competency is wrong because “the idea of isolated
societies with shared cultural meanings would be rejected by anthropologists,
today, since it leads to dangerous stereotyping (Kleinman & Benson 2006).
Understanding a cultural belief is important but a “one-size fits all” approach is
ineffective. For example, many providers believe that patients with strong
religious beliefs are more likely to be adherent. Yet, some patients believe that a
higher power gave HIV to them and these patients accept their fate and do not
take their ARVs (Kremer et al. 2009). In addition, many providers do not
understand the self-reflexive nature that cultural competency requires. Many
view the biomedical system as devoid of culture (Fox 2005, Kleinman & Benson
2006, and Taylor 2003). Without understanding how the providers and their
medical culture affect the patients, the providers cannot truly understand the
patients.
Thus, a useful method to understand a patient’s perspective is the use of an
explanatory model approach (Kleinman & Benson 2006). An explanatory model
allows the patient to make sense of his/her illness and how he/she experiences
that illness (Kleinman 1978, and Kleinman 1988). The provider can
communicate with the patient using the language of the patient and the provider
can understanding the patient’s own illness narrative (Kleinman 1988, and
Kleinman & Benson 2006). Previous research shows that the use of patient
illness narratives can be effective in understanding aspects of HIV medication
adherence and in increasing adherence itself (Wrubel et al. 2011, Scott 2009,
and Sankar et al. 2011). Some of the patients’ definitions of adherence can be
quite different than their providers. For example, a patient can change the
dosing of his/her ARV without consulting his/her clinician. While a provider would
consider this patient noncompliant, this type of patient may feel that he/she was
adherent to the medication because he/she still took them (Hill et al. 2003).
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Understanding the explanatory models of patients includes aspects such as
whether or not the patients believe in the efficacy of HAART and if they
understand how the medications work (Chesney 2003). Providers also need to
comprehend the definitions and language of their patients. Simply recalling
information does not guarantee adherence, especially when that information is
not understood (Hunt et al. 1989). Living with HIV is a personally experienced
illness in which the meaning of the disease can be different for each patient
(Scott 2009). For example, some patients view their status as a form of
punishment for past behaviors (Scott 2009). Some patients perceive their bodies
as frail while others view their bodies as strong and able to “withstand” HIV
without medications (Hill et al. 2003). Other patients can become confused in
regards to the importance of adherence. Adding to this confusion, sometimes
providers place patients on structured treatment interruptions (STIs), after
harping on the importance of adherence for months. This conflicting information
can confuse patients about the importance of adherence (Adam et al. 2003).
Adhering to any type of medication, not just an ARV, is difficult and barriers often
develop. Additionally, therapies for chronic conditions are harder to adhere to
over time. Patients who suffer from chronic conditions, like HIV, have to make
their medications a part of their daily lives and adhere to the treatment for the
rest of their lives (Polaschek 2003). These patients may need assistance in
increasing their personal care goals and self-efficacy to manage their disease.
This means that patients must be educated about their health issues and
empowered to take control of their medications (Jerant et al. 2005).
Studies show that it is difficult for people to adhere to simple regimens that only
require one pill to be taken once a day (Osterberg & Blaschke 2005). Unlike
many other regimens, HIV medication regimens have a high pill burden. Most of
the HIV medication regimens prescribed to the patients in this study required the
patients to take two to three different medications. Many of these regimens
consisted of multiple pills that were prescribed at different times of the day.
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Although there are improvements in simplifying these regimens, HIV medications
continue to be one of the most difficult regimens for patients to adhere to
(Osterberg & Blaschke 2005).
While a number of internal and external factors that create barriers to adherence
exist, ultimately it is the tolerability of the medications that plays the most
significant role in determining adherence (Hawkins 2010). If a patient cannot
tolerate the medication and its adverse effects, it is likely that the patient will have
difficulty adhering to the therapy.
Side Effects and Medication Toxicity:
All medications have some type of adverse effects or side effects, which are the
unintended physiological reactions a person has to a given medication. Some
side effects are mild and may dissipate after taking the medication for a few
weeks. Other side effects can persist for as long as the patient is taking the
medication (Remien et al. 2003). The experience of side effects is an
individualized phenomenon. There are varying degrees of these effects and
patients may conceptualize the side effects differently. Scientifically, side effects
are the secondary reactions to the medication, while the primary reaction treats
the intended illness. Yet, a patient’s beliefs about side effects can be culturally
based. Vomiting and diarrhea, while considered side effects to the medical
community, some cultures view as part of the natural healing process (Etkin
1992).
Unfortunately, it is the long-term side effects that many HIV+ patients suffer.
Some of these side effects are so serious that they can make patients feel sicker
than the virus alone does. Patients must determine how they feel about their
medications and if they are to manage the side effects. Some patients learn to
deal with the side effects (Shoemaker & Ramalho de Oliveira 2008). While
others refuse to take a medication that makes them feel sicker (Adam et al.
2003), other patients feel that the medications take control over their lives
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(Dolovich et al. 2008). Some patients become complacent with the side effects
because the side effects may kill them faster than the disease (Shoemaker &
Ramalho de Oliveira 2008). Understanding patients’ personal and cultural beliefs
on side effects is important to aid in adherence because without this
understanding, providers may be unable to conceptualize what it is like for their
patients to experience these side effects.
One of the most serious types of side effects is medication toxicity (Chesney
2003). This occurs when a medication is too strong for the body and becomes
toxic, causing the patient to develop additional, and sometimes deadly, health
problems. The patient is dependent upon the medication to fight the virus to
maintain his/her health. Because of the medication’s toxicity, if the patient
continues to take the medication everyday, he/she will become sicker.
Medication toxicity typically does not dissipate over time (Clifford et al. 2009).
While adherence to ARVs is difficult, a HIV+ patient who develops toxic reactions
from his/her medication now suffers from multiple life-threatening conditions.
Little is known about the long-term effects that HAART has on the aging body
because HIV medications are relatively new (Max & Sherer 2000, McPhail &
Robertson 2011, Palmisano & Villa 2011). Unless a cure is found, HIV+ patients
will rely on these medications for the rest of their lives. It is difficult to predict
what types of reactions their bodies will have to these medications when taken
for a prolonged period of time. Even less is known about the long-term effects
caused by ARV toxicity because clinical studies are typically not long enough to
capture this information (Hawkins 2010). Sadly, many believe that investing time
and money in understand the long-term effects of the current HIV medications is
not cost-effective since, due to the highly mutative nature of the virus, patients
are in constant need of new medications to repress viral replication.
Medication toxicity is a unique factor for studying adherence. Every patient’s
body is different, and because of pharmacogenetic variability (biological
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individualism) there is no way to predict how a patient will respond to a
medication or what the side effects will be (Cressey & Lallemant 2007). While
guidelines for the prescribing and dosing of these medications exist, ultimately, a
provider needs to know his/her patients and watch how each individual reacts to
the medications. To do this, a provider must develop rapport with his/her
patients. Trust and honesty are necessary in the patient-provider relationship.
The doctor needs to ask tough questions that deal with the personal factors that
affect adherence like alcohol and drug use, physiological and emotional health,
and personal feelings about health and therapy. The patient also needs to feel
comfortable answering these questions truthfully. Only with complete honesty
will the doctor understand how the medication affects the patient and gauge what
types of adherence barriers need to be addressed.
It can be difficult for patients and providers to have these necessary
conversations. The social, physical, emotional, and psychological aspects of
living with HIV are extremely personal, and such conversations delve into the
intimate parts of peoples’ lives. Moreover, studies show that such conversations
between patients and providers are typically awkward (Barfod et al. 2006). It can
be hard for patients to open up and be honest with their doctors because the
doctors are the ones with the power in the relationship (Osterberg & Blaschke
2005). The clinicians control whether or not the patients can receive therapy,
and many patients just want to tell the doctors what the doctors want to hear
(Osterberg & Blaschke 2005). It is not uncommon for doctors to judge their
patients (Trostle 1988), and not address the social stigma associated with having
HIV and this can emotionally affect patients (Rintamakami et al. 2006).
Renal Toxicity:
Toxicity is a serious concern when using HAART, and some forms of medication
toxicity are fatal. One of the newest forms of HAART associated with toxicity
involves particular HIV medications that affect a patient’s kidneys. In fact,
regardless of renal toxicity, a correlation between HIV and kidney problems
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already exists. Due to the nature of HIV, and the way it compromises the
immune system, many HIV+ patients already have renal problems (Post et al.
2008). Kidney disease is the third leading cause of death in HIV+ patients
(Santos, Seguro, & Andrade 2010), and 30% of HIV+ patients have abnormal
kidney function (Singer 2009). In fact, when renal problems develop, over a third
of the time, US doctors immediately check to see if the patient contracted HIV
(Rao 2001). The virus not only infects CD4-cells but also compromises cells in
the kidneys causing renal problems and can ultimately cause renal failure.
Renal toxicity is a major threat to patients’ health, and some medications
(including several HIV medications) are nephrotoxic. By taking these
medications patients may experience a side effect in which their medications
causes additional problems with the kidneys and may ultimately cause kidney
failure, which can be fatal (Roling et al. 2006 and Daugas, Rougier, & Hill 2005).
Due to the limited number of HIV medications, pharmacogenetic variability, and
drug-resistant strains of HIV, patients require these medications even though the
medications may eventually harm the patients. Statistically, most patients never
develop these fatal renal problems, so their best chance at survival is taking
these potentially harmful medications (Post et al. 2008). HIV+ patients that
develop renal side effects from their HIV medications must undergo dialysis
treatment in order to continue their necessary ARV treatments.
Some of the nephrotoxic medications are excreted through the kidneys. If left in
the body these medications would become even more toxic and would kill the
patient. The provider and patient face a puzzling dilemma. If the patient were to
stop taking the medication, the virus would mutate, rendering the medication
ineffective and HIV would replicate throughout the bloodstream eventually
compromising the patient’s immune system, leading to death. Yet, if the patient
continues to take his/her medication every day, as prescribed, the kidneys could
not flush the medication out of the body thus making the medication toxic, killing
the patient. Due to this predicament, doctors, pharmacists, drug companies, and

!

"&!

researchers advise providers to change the dosage of the medication and follow
specific guidelines called renal dosing.
Renal dosing itself is not new and is used on a variety of medications. Since the
kidneys cannot excrete the medication out of the body, placing more medication
in the body becomes dangerous. The doctor changes how often the patient
takes the medication so that the medication can still be effective, while not
becoming overly toxic. The protocol for renal dosing is different for each
medication, but for most of the HIV medications that are still used today, the
doctor instructs the patient to take the medication only after dialysis treatment,
which is typically once or twice a week. By following this strategy, the body takes
in the medication and that single dose will remain in the body to combat HIV until
the next dialysis treatment. The dialysis treatment removes the medication from
the body; thus, another dose of the medication is needed. While renal dosing is
not perfect in combating the virus, pharmaceutical research show that it is
effective in keeping HIV from destroying the patient’s immune system (Gilead:
Pharmaceutical Manufacturer, Highlights of prescribing information).
While providers utilized renal dosing strategies since the 1950s, the renal dosing
of HIV medications is still relatively new in the medical world. It was not until the
early 2000s,that the medical community discovered the need for renal dosing in
HAART. Until a few years ago, all of the literature stated that HIV medications
could only be effective if taken every day. The addition of renal dosing greatly
changed the way in which providers prescribe HAART. Even with the number of
adherence interventions, noncompliance with HIV medications continues to be a
major issue for patients placed on renal dosing (Santos, Seguro, & Andrade
2010). Although mortality rates for HIV+ patients decreased over the years,
mortality rates for HIV+ patients with renal problems remains high (Rodriguez
2003).
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Tenofovir and Toxicity:
Over the years the medical community identified various nephrotoxic medications
and replaced many with newer and safer medications. This thesis focuses on
one recently identified nephrotoxic ARV called Tenofovir, also known by its brand
name: Viread (Bruggeman, Bark, & Kalayjan 2009, Kearney et al. 2004).
Tenofovir is an HIV medication in the class of nucleotide reverse transcriptase
inhibitors (NRTIs). NRTIs work by preventing HIV from changing the genetic
coding of CD-4 cells, stopping the cell from making new copies of the virus.
Tenofovir is a newer medication and the FDA approved it in 2001 (FDA:
Antiretroviral drugs used in the treatment of HIV infection). The medication is a
successor to previous medications that patients found less tolerable. A single
dose of Tenofovir, once a day, is effective to stop HIV replication, making it a
very popular medication in drug regimens. Tenofovir is also an active ingredient
in many of the combination medications that combine multiple HIV medications
into one pill.
While Tenofovir is extremely effective in combating HIV, studies show that the
medication can cause renal problems (Gallant & Moore 2009, Karras et al. 2003,
Schaaf et al. 2003, Zimmerman et al. 2006). The pharmacogenetic variability of
the medication is diverse. Patients react differently to the medication and there is
no way to predict if renal toxicity will occur. After years of testing and years on
the market, the initial data did not show any correlation between the medication
and renal problems. As the years passed studies began to reveal that Tenofovir
caused renal problems. An explanation for the lack of initial data is that
prolonged use of the medication increases the likelihood of renal issues (Rosso,
Ginocchio, & Bassetti 2008, Coca & Perazella 2002). While there is some
literature on these adverse events, the literature is still scarce. At the present
time only 2% of the HIV population in the United States suffer from renal
problems caused by Tenofovir (Hamzah & Post 2009). While this may not
appear to be a major medical concern, some researchers and doctors believe
that the incidence of renal dosing will greatly increase in the next few years

!

"(!

(Wanner, Tyndall, & Walker 2009). The popularity of the medication (Shepp,
Curtis, & Rooney 2007), combined with prolonged use, may result in an increase
of renal problems.
With both limited kidney function and compromised immune systems, it is
extremely important that HIV+ patients with renal complications adhere to their
medication regimen even while they are on renal dosing. If the virus is
uncontrollable it can cause serious health problems for patients with a
compromised renal system. Even with the adverse problems associated with the
medication, HAART therapy is still effective in patients undergoing dialysis
(Ahuja, Borucki, & Grady 2000). While adherence for this group of people is
extremely important, almost no research is conducted with them. This is
probably because renal dosing of HIV medications is still new to the field. This
makes renal dosing a factor in adherence that deserves further research.
Understanding drug toxicity and the barriers it presents is important in
determining whether patients will adhere to their medication regimens (Szczech
et al. 2002).
While adherence is an issue for all HIV+ patients, those on renal dosing have
additional issues that need addressing. There is no set standard of renal dosing
for providers to follow. While the drug companies supply guidelines, patients are
unique and the medication may react differently with each patient, making the
dosing dependent on the level of renal problems each patient has (Kearney et al.
2004). This means that providers must be attentive to patients who have renal
issues and take these renal problems into account when prescribing medications
(Papaioannou et al. 2000).
Due to the large number of patients it can be difficult for providers to keep up to
date on all of their patients. Unfortunately, some medications are incorrectly
prescribed to patients (Rodriguez 2003), and some studies suggest that many of
the nephrotoxic medications are overprescribed (Papaioannou et al. 2000). In
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addition, some HIV+ patients do not receive adequate dosing of their
medications to suppress the virus (Szczech et al. 2003). This variability in the
recommended dosing makes it difficult for providers to prescribe the right dosing
for their patients. Ultimately, prescribing can become a trial and error method. In
situations like this, good rapport with patients is again vital for the patientprovider relationship. Doctors need to understand patients’ lived experiences and
the patients need to trust their doctors. Without a good working rapport, this is
nearly impossible (Tourret et al. 2007).
There is an added burden on the patient-provider relationship for renal dosed
patients. Two of the groups that renal dosing affects the most are African
Americans (AA) and Intravenous Drug Users (IDUs), who often have poor
rapport with providers (Bogart et al. 2010). This places even more demand on
providers to strengthen their relationships with these patients because incorrect
dosing can lead to increased toxicity and adverse events, which, in turn, can
decrease adherence and cause drug resistance (Willig et al. 2007).
Even when providers find the correct dosing, human error can still occur. In a
number of hospital studies, doctors and nurses made errors in the dosing of this
medication. The doctors and nurses administered suboptimal therapy (Ahuja,
Grady, & Khan 2002), which led to complications that resulted in decreased
survival rates (Tourret et al. 2007). Patients not receiving the correct dose of the
medication was the cause of some these errors, but patients not receiving the
medications at the correct time was the cause of most of the errors (Tourret et al.
2007). For patients on renal dosing, there is a specific time frame within which
the medications should be administered, and many of the hospital workers did
not give the medications to the patients in accordance with these guidelines
(Tourret et al. 2007).
If patients receive suboptimal therapy in the hospitals, where trained
professionals administer the medications, then adherence in the home, where
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patients take their own medications, must be a high priority and should be
studied more. Many renal dosing patients travel to a dialysis center. Since the
patients travel, the patients need to remember to bring their medications with
them and take the medications at the proper time. Although there are health
care professionals at the dialysis centers, these professionals are not the HIV
care providers. Thus, the HIV clinicians do not know whether their patients are
taking the medications at the proper times.
HIV medication regimens have a high pill burden and it is difficult for patients to
adhere to them (Wensing, van Maarseveen, & Nijhuis 2010). HIV regimens
usually include multiple medications that must be taken every day. Patients on
renal dosing have a higher pill burden than other HIV+ patients. Renal dosing
patients must remember to take some of their medications every day as originally
prescribed, and the renal dosing medications only after dialysis. It can be
challenging for HIV+ patients to remember to take their pills every day. Changing
patients’ regimens to renal dosing greatly increases the chances of
noncompliance because patients must remember to take some of their
medications everyday and other medications only a few times a week. This is
difficult for patients who were on their medications for a prolonged period of time
and developed pill-taking habits.
Renal dosing patients, like many other HIV+ patients, suffer from comorbidity, the
presence of two or more diseases. Managing one disease is difficult, but
managing multiple diseases is extremely problematic (Bayliss, Ellis, & Steiner
2007). Comorbidity in HIV+ patients increases the likelihood of opportunistic
infections and a compromised immune system (Ahuja, Grady, & Khan 2002).
Patients must adhere to therapy for all of their illnesses because if they are
noncompliant with a therapy their health can deteriorate. Patients who have
multiple chronic conditions have increased health burdens. By increasing
patients’ self-efficacy and agency, providers can assist in the adherence to
medication therapies.
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While these factors affect a number of HIV+ patients with comorbidity, renal
patients have additional factors. Due to the unique dosing regimen of this group,
and the pharmacogenetic variability of the medications, the medications may not
be potent enough to be effective. Even when patients are adherent to their
regimen, there is no guarantee that the medications will be effective (Cressey &
Lallemant 2007). This can become frustrating for patients and the providers, and
typically both find something or someone to blame (Maskovsky 2005). In
situations such as this the providers may place the blame on the patient, while
the patients may place the blame on the therapies (Rousse 2010). In scenarios
such as this, the chances of adherence are greatly reduced because the rapport
between provider and patient is lost (Seema et al. 2011, and Beck & Gordon
2010).
The therapies used to treat HIV+ patients on renal dosing are complicated and
the adverse effects can cause additional health problems for the patient (Singer
2009). Adverse effects like drug toxicity greatly interfere with the daily routines of
patients, which, in turn, can affect adherence (Remien et al. 2003). Patients
need to believe that the medications are helping them even when the side effects
are detrimental to their health. If patients believe the medications are hurting
them, complications usually arise in adherence (Remien et al. 2003).
Patients on renal dosing receive at least two types of therapy for their chronic
conditions. They receive HAART for their HIV and dialysis for their kidney
problems. It is hard for some patients to trust in either of their therapies because
the therapies can become iatrogenic syndemic. Iatrogenic syndemics occur
when the healing therapies used to treat conditions in a comorbid patient cause
adverse effects that make the disease not treated by the medication worse
(Singer 2009). For renal-affected HIV+ patients, taking nephrotoxic HIV
medications stops HIV replication but causes kidney damage or failure. Some
studies show that dialysis treatments can make HIV replicate at a faster rate
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(Ahuja, Grady, & Khan 2002). Thus, undergoing dialysis treatments allows
patients to excrete the toxic waste from their bodies but may cause faster virus
replication. Patients must adhere to both therapies for survival, yet each therapy
can make the other condition worse. This makes the patients even more reliant
on the treatment, which in turn can cause the conditions to worsen.
Noncompliance for those who are on ARV and dialysis treatments is common (as
cited by Curtin, RB et al. 1999, Leggat, JE et al. 1998, and Kimmel, PL et al.
1995 in Loghman-Adham 2003), and this cycle may make it worse.
Review:
In sum, adherence to an antiretroviral (ARV) medication regimen is necessary for
seropositive individuals to survive. Due to the vast number of factors and
difficulties people experience from living with HIV, barriers to medication
adherence develop. Understanding these barriers and helping HIV+ people
overcome them can greatly increase rates of adherence. However, little
research is conducted on the barriers to adherence for people living with HIV that
providers place on a renal dosing ARV medication regimen. In addition, this
population experiences unique conditions in living with HIV. This can result in
specific barriers to adherence for population. Thus, more research needs to be
conducted on adherence and the barriers to adherence for this population.
LifeWindows Project Background:
The LifeWindows project (Fisher et al. 2011) is a psychological research study
headed by Dr. Jeffrey Fisher, head of the University of Connecticut’s Center for
Health, Intervention, and Prevention (CHIP). I worked for Dr. Fisher as a
researcher on this project. The team developed the survey instrument and
protocols for the study prior to my arrival. My roles as a researcher included: the
testing of the computer program, participant recruitment, participant retention,
working with patients, running participants through the LifeWindows program,
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and administrative duties. Dr. Fisher and the research team gave consent for
use of project data for this thesis.
The team conducted the study at five HIV clinics located throughout the state of
Connecticut. PhDs, administrative and support staff, and an on site researcher
for each of the HIV clinics comprised the LifeWindows Project team. This was a
voluntary study and all participants gave written, informed consent to participate
in the research. The Institutional Review Boards (IRB) at the University of
Connecticut and at each of the HIV clinics approved this research.
LifeWindows Computer Program:
LifeWindows is an interactive computer based ARV adherence support
intervention. The computer program worked with HIV+ patients based on the IMB
model of adherence in order to assess patient adherence, identify barriers to
adherence, and test the efficacy of specific adherence interventions.
As previously discussed, the IMB model of adherence works on the premise that
information, motivation, and behavioral skills are critical factors that affect
adherence and those patients that possess these skills can apply them to their
ARV regimen. The IMB model also suggests that identifying the barriers to these
skills and addressing them can increase patients’ adherence. The study included
both a control arm and an intervention arm. Participants in both arms used the
LifeWindows computer program, but only those patients in the intervention arm
had exposure to the adherence interventions.
The computer program consisted of several components. The first component
was a tutorial that explained basic computer usage and how to use the
LifeWindows program. Each time a patient entered the program Marcus, a
virtual guide, greeted the participant, introduced him/her to LifeWindows and
helped him/her navigate through the computer program.
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After Marcus’s greeting, the patient completed a general assessment module.
The first part of this module elicited background information and demographic
characteristics (these survey questions are in Table 7 located in the Appendix) by
allowing the patient to choose from a list of provided responses. The patient
completed the survey by using the mouse to click on the responses. Due to the
nature of these questions, the responses ranged from binomial (yes/no)
responses (e.g., Are you currently taking a break from your HIV medications
without talking to your healthcare provider?) to questions that provided over 20
responses to choose from (e.g., In what year were you diagnosed with HIV?).
Also, some of the questions asked for a single response while others asked for
all responses that applied (e.g., How did you first get HIV?) During the baseline
session of LifeWindows the patient completed the entire survey. On subsequent
sessions the patient only responded to questions about things that could have
changed since the last visit. The patient could also to choose “Prefer not to
answer” for all of the questions.
The second part of the module was a survey of possible barriers to adherence
(the survey questions are in Table 8 located in the Appendix). Like the
demographic survey, this part of the module showed the patient responses for
each question. Also like the previous survey, the number of responses was not
uniform. Many of the questions’ responses were Likert scales. The survey
looked for barriers to adherence based on the IMB model. Thus, questions
asked focused on the patient’s informational, motivational, and behavioral skills.
The patient had the option to choose “Prefer not to answer” for all of the
questions.
The final portion of this module was an interactive survey to assess ARV
adherence. The module started with a section called the “Pill Picker.” In this
section the patient chose all of the HIV medications that he/she was prescribed.
To help the patient choose the correct medications, the program showed pictures
of each ARV medication. The list included both brand and generic medications
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that were in use during the time of the study. Also the patient could sort the list
by the medications’ name, size and shape, or function.
Prior to the patient’s session of LifeWindows, the site researcher would examine
the patient’s medical chart and update the program’s database with the current
ARV medications. During the “Pill Picker” section, if the patient failed to choose
the correct medication or chose a medication that was not in the database, the
program took the patient to the “Discrepancy” section. In this section the
computer showed the patient which medications were listed in the database and
which medications he/she chose. The patient then choose the medications that
he/she believed he/she was on, which would override the discrepancy if
necessary, but would create a report for the team to examine at a later time.
When completed, or if no discrepancy existed, the system brought the patient to
the adherence survey.
The adherence survey asked the patient to report on his/her adherence over the
last three days and over the last four weeks. The system displayed a daily
calendar for each of the ARV medications. Then the program asked the patient
to choose the times during the day and the number of pills prescribed for each
HIV medication. The program asked the patient to report whether he/she took
each medication over the last three days and how many pills he/she took at that
time. The patient reported his/her adherence in the form of a percentage with
0% signifying that he/she took no medications, to 100%, which signified that
he/she took all medications as prescribed. The computer asked the patient to
report on each medication for the past three days and then for the past four
weeks.
This was the end of the program for those patients in the control arm of the
experiment. The patients in the intervention arm went on to receive an adherence
support component that had 20 different individually targeted intervention
activities. The patients interacted and completed the activities on the computer.
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The activities included things such as: an informational movie, asking experts
specific questions, a computer game, receiving relevant information, and a
variety of other activities (the listing and description of the intervention modules
are in Table 9, located in Appendix). The computer program kept a record of the
survey questions that positively identified possible barriers to adherence from the
general assessment. Each of these questions linked to a particular adherence
strategy (a list of these strategies is in Table 10 located in the appendix). After
completing the general assessment the patients in the intervention arm chose
from a list of adherence strategies that they could work on while in LifeWindows.
The strategies linked to the survey questions that identified a possible barrier to
adherence. After choosing a strategy, the patients chose which interventions
they wanted to complete. The patients selected the intervention they wanted to
work on and engaged in the activity. Each of these interventions addressed
specific adherence strategies. The purposes of these interventions were to
increase patients’ information about HIV and HAART, increase patients’
motivation about taking medication, and change patients’ behavioral skills in
taking medications. Table 11 (located in the appendix) shows which strategies
and interventions linked to each question.
After completing the interactive activity the patient went to a goal selection
module. In this module the patient chose an adherence related goal. The
program presented some already prepared goals on the screen. These goals
focused on the patient’s self-identified barriers to adherence and the intervention
the patient completed. The patient could also create a personal goal. The
system printed the goal and presented it to the patient. On subsequent visits
Marcus asked the patient about his/her progress on the goal.
The LifeWindows session concluded with a farewell message from Marcus,
reminding the patient to return to LifeWindows during the next doctor visit. On
the final LifeWindows session, or exit survey, Marcus thanked the patient for
his/her help in the study.
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LifeWindows Survey Questions:
As previously discussed, the LifeWindows computer program consisted of three
different computer delivered surveys: demographic information, adherence
barrier identification, and adherence to HAART medication regimen. The data
used in this thesis focuses mainly on the adherence barrier identification survey.
The LifeWindows research team developed these questions to identify possible
barriers to adherence that affected participants in the study. Nearly all of the
responses to the questions were Likert scales. Each time the patients
participated in a LifeWindows session, the program asked the same 45
questions. Of the 45 questions, only 34 linked to an adherence strategy. The
remaining questions still identified barriers to adherence, but did not affect the
LifeWindows session.
Barriers Identified in LifeWindows:
The questions, responses, strategies, and interventions identified in this thesis all
came directly from the LifeWindows program, and the LifeWindows team
developed them using the IMB model of adherence, research from previous
studies, and consultations with HIV clinicians. While the general assessment
identified barriers to adherence, the research team did not name each specific
barrier. For this thesis I created the names for the barriers to adherence based
on each survey question and its linked adherence strategy. The full list of
barriers addressed through the strategies and interventions are in Table 12
located in the appendix.
The LifeWindows program identified a total of 37 barriers, based on the IMB
model of adherence. Since there were 45 survey questions and 34 adherence
strategies, some of the barriers correlated with multiple questions. The research
team developed these questions because they believed that barriers could exist
for people in a variety of ways. Developing the questions in this manner allowed
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the team to identify more barriers to adherence, and with these barriers the
program routed the patient to the appropriate intervention.
LifeWindows Results:
The LifeWindows study tested the hypothesis that those patients exposed to the
interventions would have greater adherence over time than those patients in the
control arm, because the interventions better addressed the barriers to
adherence than the patients’ previous exposure. The purpose of this study was
to test the hypothesis and, if proven, to determine which interventions most
improved patients’ adherence. The study found that the intervention significantly
improved adherence (Fisher et al. 2011).
Participants for this Thesis:
The team recruited 590 participants for the LifeWindows study. The criteria for
inclusion into the study were that each participant had to be: HIV+, a patient of
the clinic, 18 years of age or older, on ARV therapy at baseline, and competent in
the English language at a fourth grade reading level. Recruitment occurred at all
five of the HIV clinics. Each clinic had affiliations with its own hospital and its
location was within or next to the given hospital. Four of the five hospitals were
cities in poor neighborhoods in the state. Most of the participants were minorities
from a lower socio-economic status.
Nurses, physician assistants, and doctors staffed the clinics. The number of
times patients frequented the clinic depended on their physical health. Patients
who were not healthy and whose viral load was high came in every month;
patients who were in good health only came in every three months; and patients
who were in excellent health and who had an undetectable viral load came in
every six months. The frequency of visits was one of the few characteristics that
differed between the sites. Patients who were in better health and who visited
the clinic less often came mostly from the one clinic located in the suburb. The
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only other notable difference was that the clinic located in the suburb had a
higher socio-economic population.
The clinicians referred all participants to the team and the participants freely
chose whether they wanted to take part in the study. Each on-site researcher
randomly assigned his/her participants into either the control or intervention
conditions. After recruitment, the patients completed informed consent
procedures and baseline measures by participating in their first LifeWindows
session.
The participants interacted with LifeWindows for approximately 18 months
between March 2006 and March 2008 in a private location in the HIV clinic prior
to seeing their provider for routine HIV medical visits. Patients could complete up
to one LifeWindows session a month and received $20 for each session they
completed.
Of the 590 patients recruited in the study, 12 had their regimen changed to renal
dosing during the study period. Throughout this thesis the group of individuals
placed on renal dosing is the renal dosing group (or RD), while the entire sample
population is SP.
Similarities between the Sample Population and Renal Dosing Group:
Most of the demographics and characteristics of the RD were similar to the SP.
Throughout both populations in the study there were slightly more male than
female patients (SP= 61.2% male, RD= 58.3% male). Most of the population
identified themselves as heterosexual (SP= 74.1% and RD= 83.3%). There was
a slight difference between the groups among those who did not identify
themselves as heterosexual. In the total sample 19.2% of the population
identified themselves as homosexual and 6.7% identified themselves as
bisexual. In the renal sample only 8.3% identified themselves as homosexual
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and another 8.3% identified themselves as bisexual. Also, most patients had few
to no children (SP= 1.17 children, RD= 0.3 children).
Most of patients in the study lived with HIV for more than ten years (SP= 13.25
years, RD= 14.18 years). While this is not a significant difference there is a
chance that the years lived with HIV may be correlated with being on renal
dosing. Since long-term use of Tenofovir can cause kidney problems, the longer
a patient takes the medication the more likely he/she is to develop renal issues.
Due to the small sample size of RD this thesis cannot test this hypothesis, but
this may warrant future testing.
The most significant characteristic that the two groups shared was their living
situation. The vast majority of the populations lived in stable housing (SP=
90.9%, RD= 91.6%). The living situations of the patients did not appear to be a
factor that affected adherence, yet very few patients had employment (SP=
39.3%, RD= 25%). This characteristic greatly affects the socio-economic status
of the patients and can impact their adherence. On average, the patients in the
study lived close to or below the poverty line (SP= $17,219 a year, RD= less than
$10,000 a year). I expected this result because those patients on renal dosing
would work less and make less money than other patients due to the physical
problems and limitations that kidney failure causes. It is important to note that
this survey question asked about family income and there was no way to
determine if participants included other sources of income (such as welfare or
supplemental security income) when they answered this question. This data
show that income is a characteristic correlated with RD and may be a barrier to
adherence. Income may also be a barrier for SP since less than 40% of the
patients in the study found employment.
Differences between the Renal Dosing group and the Sample Population:
While the two groups shared many characteristics there a number of
characteristics differed. The most notable of these was race/ethnicity. Most
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patients in the study were minorities. For both samples African American (AA) or
Black was the largest ethnic group that patients identified. The sample
population was 44.1% Black, while the renal dosing group was 66.6% Black.
Although this is a significant difference, the difference in the sample sizes may
skew the findings. It is interesting to note that in the general population kidney
problems concentrate among those who are Black (Bogart et al. 2010).
While many patients in both samples contracted the virus through heterosexual
intercourse (SP= 39.1%, RD= 41.6%), the groups differed on the other ways the
patients contracted the virus. The largest difference was for those who
contracted HIV due to intravenous drug use (SP= 21/2%, RD= 41.6%). While the
size of the sample may skew the findings, this is also interesting because like
being AA, IDUs are also more likely to develop kidney issues than non-IDUs in
the general population (Bogart et al. 2010). These characteristics and further
information are below in Table 1.
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Table 1: Demographic Information and Characteristics

Characteristic
Male
Female
Years with HIV
Number of children
Heterosexual
Homosexual
Bisexual
Living in stable housing
Black/ African American
Latino/a
White
Other
Employed
Yearly income
HIV infection: MSM
HIV infection: Heterosexual sex
HIV infection: IDU
HIV infection: Blood transfusion
HIV infection: Multiple ways
HIV infection: Unknown
HIV infection: Refused to answer
HIV infection: Sex but gender
unknown

Total Sample
Population
361 (61.2%)
229 (38.8%)
13.25
1.17
431 (74.1%)
112 (19.2%)
39 (6.7%)
538 (90.9%)
262 (44.1%)
151 (25.4%)
141 (23.7%)
40 (6.7%)
233 (39.3%)
$17,219
85 (14.3%)
232 (39.1%)
126 (21.2%)
15 (2.5%)
54 (9.1%)
73 (12.3%)
6 (1.0%)

Renal Dosing
Group
7 (58.3%)
5 (41.6%)
14.18
0.3
10 (83.3%)
1 (8.3%)
1 (8.3%)
11 (91.6%)
8 (66.6%)
1 (8.3%)
3 (25.0%)
0 (0.0%)
3 (25.0%)
Under $10,000
2 (16.6%)
5 (41.6%)
5 (41.6%)
0 (0.0%)
2 (16.6%)
2 (16.6%)
0

2 (0.3%)

0 (0.0%)

Data courtesy of the LifeWindows Project Team 2006
Data:
The LifeWindows project tested the hypothesis that by exposing HIV+ patients to
interventions that addressed barriers to adherence the patients’ adherence rates
would increase. Prior to the study, the literature and conversations with
providers, all stated that patients must take their ARV medications every day at
the same time in order for the medications to be effective. The team designed
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the computer system and study in this manner to measure adherence by tracking
whether or not patients took the prescribed dose of each medication every day.
During the study providers changed the ARV regimen of several of their patients.
Among these were 12 patients that the clinicians placed on renal dosing. These
patients suffered from kidney problems that required dialysis. Since the body
excretes these HIV medications through the kidneys, the providers changed
these medications before they became toxic for these 12 patients. The providers
changed the dosing for these medications from once every day to once or twice a
week following a dialysis treatment.
Since the design of the LifeWindows computer program only tracked adherence
on ARV medications taken every day, the automated program for adherence
could not assess adherence for these 12 patients. While adherence was not
tracked, the automated program captured the barriers to adherence that these
patients positively identified. My thesis examines these barriers to adherence to
see if any of them are unique to this population and to better understand the lives
of these patients to help increase adherence rates for HIV+ patients placed on
renal dosing.
Examining the Data:
The examination of the case notes made by the site researchers identified the
renal dosing patients in the study. This examination yielded 12 patients placed
on renal dosing during the study. These 12 patients hereafter are the renal
dosing group and the rest of the sample is the normal dosing group.
As previously discussed, each time a patient completed a session of
LifeWindows he/she answered 45 survey questions that identified 37 possible
barriers to adherence. The responses for these 45 questions ranged from two to
six options (with an additional response of “refuse to answer” for each question).
For the analysis of this thesis, I coded the responses binomially for uniformity. If
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the response did not identify a barrier or if the patient chose “refuse to answer”
the coded response was a 0. Since “refuse to answer” did not identify a barrier,
coding as a 0 omitted this response from the data set. This coding scheme is
useful in survey research because refusal to answer is usually unrepresentative
of a sample and does not change data set (Kent 2001). If the response identified
a barrier the coded response was a 1. These criteria were the same as those
used in the LifeWindows adherence algorithm that identified which intervention
strategies the LifeWindows program showed the patients.
The patients’ responses were then sorted chronologically by each LifeWindows
session they completed. For this thesis I only used the baseline and final survey
responses to identify and analyze the barriers to adherence. These two time
frames best compare the responses of patients in each of the dosing groups.
Since all patients entered the study while on normal ARV therapy dosing, the
renal dosing group did not exist at baseline. Those patients placed on renal
dosing remained on a renal dosed regimen throughout the remainder of the
study. The final survey clearly divided the normal dosed patients from the renal
dosed patients. The final survey responses also reflect longer lasting barriers to
adherence because the patients had months to acclimate with the change in their
medication regimen.
Thus, patients had to complete at least two sessions of LifeWindows to be in the
samples for this thesis. This thesis does not include data from patients who only
completed a baseline survey. The thesis also does not include data from
patients who failed to answer all of the questions during the baseline or final
surveys. This provides an accurate range to detect the barriers identified by
patients. The final sample included 12 patients in the renal dosing group and
513 patients in the normal dosing group. While the total sample had 590
participants, due to attrition or lack of answering all questions, only 513
participants remained in the normal dosing group in this analysis.

!

$%!

Data Analysis:
The analysis of the data used the SPSS statistical software package. The
analysis used Paired Sample T-Tests, Independent T-Tests, and Chi Squared
tests to examine whether there were significance differences between the two
groups and to identify significant barriers to adherence.
Results:
I analyzed the data to see if there were specific barriers to adherence that only
the patients on renal dosing identified as a barrier. I hypothesized that the switch
to a renal dosed regimen would increase the barriers and difficulties patients had
in adhering to their ARV medications. In this analysis I examined the overall
number of barriers identified by the patients and looked at each survey question
to determine if it disproportionally affected those patients on renal dosing. When
I found barriers that greatly affected the renal group, I then examined these
barriers further to better understand them and offer recommendations on how to
help this population increase adherence.
Based on the 45 questions from the LifeWindows survey, each patient identified
between 0 and 45 questions that positively correlated with a barrier to their ARV
adherence. The total number of questions that positively identified barriers to
adherence for the renal group’s responses compared the group’s baseline and
exit surveys. A Paired Sample T-Test found an average of 18.25 questions that
positively identified barriers on the baseline surveys and an average of 14.58
questions on the exit surveys. There was no correlation or significance found in
these results. Thus, being placed on renal dosing did not increase the likelihood
that a patient would experience more barriers to adherence. This decrease in
barriers may be a result of exposure to the intervention arm of the study, but this
is unlikely. There is no indication that the reduction for renal dosed patients was
a result of exposure to the intervention arm. Like the general sample population,
about half of the patients in the renal group happened to be placed in the
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intervention arm of the study. Of the 12 participants, five were in the intervention
arm and 7 were in the control arm.
For the analysis I used an Independent T-Test to compare the total number of
questions that positively identified adherence barriers at baseline between the
two groups. This analysis showed that at baseline, on average, the total number
of questions that identified barriers was 18.25 for the renal sample and 15.64 for
the normal dosing group. Again the analysis did not find any correlation or
significance. I expected this result because at baseline, none of the providers
placed their patients on renal dosing, thus the two groups had the same number
of barriers.
The analysis also ran an Independent T-Test on the exit surveys, which
compared the same total number of questions between the two groups. This
analysis showed that at the completion of the study the two groups had, on
average, almost the same number of questions. The renal group averaged 14.58
and the sample group averaged 15.41. Again, the analysis did not find correlation
or significance. These results showed that the placement on renal dosing did not
increase the likelihood that a patient would experience an increase in the total
number of barriers experienced.
The analysis then analyzed each of the 45 questions to determine if there were
any particular responses to questions that correlated with the change to a renal
dosed regimen. The analysis used the same binomial scale on the 45 questions.
Any question that more than half of a group (renal or normal) identified as a
barrier went under further investigation. This yielded a total of 14 survey
questions that fit this profile. These survey barriers are below in Table 2.
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Table 2: Barriers to Adherence Survey Questions for Further Analysis

!

Question

Percent
Who
Responded

How hard or easy is it for you to manage the
side effects of your HIV medications?
How much bodily pain have you had during
the past 4 weeks?
During the past 4 weeks, how much did
physical health problems limit your usual
physical activities (such as walking or
climbing stairs)?
During the past 4 weeks how much difficulty
did you have doing your daily work, both at
home and away from home, because of your
physical health?
It upsets me that the HIV medications I have
been prescribed can cause side effects
During the past 4 weeks, how much energy
did you have?
I am worried that other people might realize
that I am HIV+ if they see me taking my
medications
How hard or easy is it for you to take your
HIV medications when you do NOT feel
good physically
It upsets me that the HIV medications I have
been prescribed can affect the way I look

67%

57%

Negative feelings towards
medications

How often do you use a pillbox to help keep
track of your HIV medications?
It frustrates me to think that I will have to
take these HIV medications every day for
the rest of my life
I get frustrated taking my HIV medication
because I have to plan my life around them
How hard or easy is it for you to take your
HIV medications when you do not feel good
emotionally (for example, when you are
depressed, sad, angry, or stressed out)?
How hard or easy is it for you to take your
HIV medications when your usual routine
changes (for example, when you travel or
when you go out with your friends)?

57%

Not using a pillbox or other
reminder device
Frustration that HIV medications
must be taken for life

67%
67%

Barrier Identified
Difficulty in managing the side
effects to medications
Experiencing and dealing with
bodily pain
Physical health problems limit
ability to perform daily functions

67%

Difficulty in performance of daily
work due to physical health
problems

66%

Fear of a medication's side
effects
Lack of energy

63%
58%

58%

57%

54%

Fear that others may find out
about HIV status if medications
are taken in public
Difficulty in taking medications
when not feeling good physically

53%

Frustration in having to plan life
around medications
Not feeling good emotionally

50%

Changes in one's daily routine
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For each of the questions above the analysis compared the baseline and final
surveys for each participant. The analysis then summed the total number of
patients that identified the question topic as a barrier for both the renal and
normal dosing groups. Chi square tests using Yates correlation (since the size of
the groups differed) compared the total number of barrier questions at baseline
and exit time periods for both the renal dosing and normal dosing groups.
The expected outcome was that the analysis would identify certain barriers within
the renal dosing group only, due to the additional challenges the patients in the
renal dosing group faced. The data yielded from the analysis do not support this
hypothesis. Of the 45 questions examined, only one (I am worried that other
people might realize that I am HIV+ if they see me taking my HIV medications)
was statistically significant. Surprisingly, this barrier was a problem for the
normal dosing group and not the renal dosing group. Thus, the analysis found
no barriers that significantly affected renal dosing patients more than normal
dosing patients.
The lack of statistical significance in the data analysis most likely reflects the
small sample size of the renal dosing group. While I found no statistical
significance from the quantitative analysis, I decided to conduct a qualitative
analysis by using an inductive grounded theory approach (Bernard 2004). I
examined the 14 questions that patients identified as a possible barrier to
adherence in order to identify possible trends in noncompliance. I reviewed each
of the questions and identified themes that the questions had in common. An indepth review of this analysis follows.
Discussion: Factors to Noncompliance and the Barriers to Adherence:
Through the use of the grounded theory analysis I found that there were some
questions that the renal group identified as barriers, some that the normal group
identified as barriers, and some questions that both groups identified as barriers.
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The examination of these questions and their strategies led to several possible
factors that may cause these barriers. These factors are below in Table 3.
Table 3: Factors to Noncompliance
Group Affected

Factor

Barriers that greatly affected
patients in both groups

1) Emotional well-being and psychological mindset
2) Physical Factors that lie outside of a person’s control

Barriers that affected
patients on renal dosing
more
Barriers that affected
patients on normal dosing
more
Barrier that affected both
groups but was not part of
the survey. Field site
personnel identified this
barrier.

1) Side Effects to medications
2) Physical Health problems
1) Interruptions in daily life
1) Health Literacy

Barriers for All Patients:
While not expected, the data revealed a series of barriers that affected patients in
both of the groups. The quantitative analysis did not find this because the
analysis focused on finding the differences between the two groups. The barriers
that both groups identified are in Table 4.
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Table 4: Barriers Identified by Both Groups
Question

Percent
Factor
who
Responded

Barrier Identified

It upsets me that the HIV
medications I have been
prescribed can cause side
effects

66%

Fear of a
medication's side
effects

How hard or easy is it for you
to take your HIV medications
when you do not feel good
emotionally (for example,
when you are depressed, sad,
angry, or stressed out)?
During the past 4 weeks, how
much energy did you have?

53%

Emotional
well-being
and
psychological
mindset
Emotional
well-being
and
psychological
mindset

Lack of energy

How hard or easy is it for you
to take your HIV medications
when your usual routine
changes (for example, when
you travel or when you go out
with your friends)?

50%

Physical
factors that
lie outside of
a person's
control
Physical
factors that
lie outside of
a person's
control

63%

Not feeling good
emotionally

Changes in one's
daily routine

The first two barriers identified by both groups related to the emotional wellbeing
and psychological mindset of the patient. HIV+ patients suffer from a number of
psychological and emotional issues. There are many aspects of living with HIV
that cause distress for patients and if a patient is not feeling emotionally well, this
can impact adherence (Tuck & McCain 2008). The fear of possible side effects
from HIV medications can be very distressing to patients. As previously
discussed, many medications can cause side effects, but HIV medications have
some of the harshest side effects on patients. Thus, it makes sense to find these
two barriers shared by both patient groups.
The second set of barriers identified by both groups focused on patients’
experiences in dealing with physical factors that usually lie outside of their
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control. A further review of the literature found that this trend is expected. It is
well documented that many HIV+ people experience a lack of energy due to the
virus, side effects from medications, or other health conditions (Adinolfi 2001).
The other physical barrier to adherence that both groups identified was difficulty
in adhering to a medication regimen due to a change in daily routine. This
particular barrier is also common among the HIV community although it is not
exclusive to those on HAART. In fact most people, not just HIV positive people,
forget or unable to take their medications when their routine changes (Rosner
2006 and Waller & Altshuler 1986). While these are well-known barriers, the
data show that these barriers still exist for both populations and that further
investigation into these barriers is necessary to understand the full impact that
they have on adherence.
Barriers for Patients Placed on Renal Dosing:
While not statistically significant, the data revealed a number of barriers that
affected patients in the renal dosing group more than those in the normal dosing
group. These barriers are below in Table 5.
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Table 5: Barriers for Patients Placed on Renal Dosing Schedules
Question

Percent
Factor
who
Responded

Barrier Identified

How hard or easy is it for you
to manage the side effects of
your HIV medications?

67%

Side Effects
to
medications

How much bodily pain have
you had during the past 4
weeks?
During the past 4 weeks, how
much did physical health
problems limit your usual
physical activities (such as
walking or climbing stairs)?
During the past 4 weeks how
much difficulty did you have
doing your daily work, both at
home and away from home,
because of your physical
health?
How hard or easy is it for you
to take your HIV medications
when you do NOT feel good
physically

67%

Physical
health
problems
Physical
health
problems

Difficulty in
managing the side
effects to
medications
Experiencing and
dealing with bodily
pain
Physical health
problems limit ability
to perform daily
functions

67%

67%

Physical
health
problems

Difficulty in
performance of daily
work due to physical
health problems

58%

Physical
health
problems

Difficulty in taking
medications when
not feeling good
physically

The first barrier identified by the renal group dealt with difficulties in the
management of side effects. Both groups identified that knowing that HAART
could cause side effects was barrier, but this finding may show an important
difference between the two groups. It is unclear as to whether the normal group
did not experience side effects or just did not have issues managing their side
effects. It is clear that the renal group had issues in dealing with the side effects
of their medications.
There may be several reasons why side effects are more burdensome for renal
dosed patients. As previously discussed, studies revealed that medications like
Tenofovir had the side effect of renal failure, which forced patients to receive
dialysis treatments. The reception of dialysis treatments could very well explain
this difference between the two groups.
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The comorbidity of HIV and kidney problems may also explain this difference.
Poor renal function increases the likelihood of adverse drug reactions and side
effects (Jick 1977). The combination of these two factors results in a syndemic
that may explain why this barrier is not shared with normally dosed HIV+
patients.
The remaining barriers all dealt with the physical health of the patient. While HIV
may take its toll on the body and be quite painful, the additional issues in
experiencing renal failure and undergoing constant dialysis treatments can be
much worse. Kidney failure is extremely uncomfortable and causes intense pain
in the kidney area (Pham et al. 2010). In addition to experiencing pain, dialysis
treatments can leave a patient weak and unable to perform many of his/her
everyday activities (Polaschek 2003). These barriers can affect whether a
patient is actually able to take his/her medications and the medications can also
affect the emotional mindset of the patient and how he/she feels about the
medications and about HIV.
Barriers for Patients Placed on Normal Dosing:
Since the hypothesis was that renal dosed patients would have a harder time
adhering to their medications, the data analysis attempted to find barriers unique
to those patients who were on renal dosing. Although not expected, the data
identified barriers that affected the normal dosed patients more than the renal
dosed patients. These barriers are below in Table 6.
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Table 6: Barriers for Patients Placed on Normal Dosing Schedules
Question

Percent
Factor
who
Responded

Barrier Identified

I am worried that other people
might realize that I am HIV+ if
they see me taking my
medications

58%

Privacy

It upsets me that the HIV
medications I have been
prescribed can affect the way I
look
How often do you use a pillbox
to help keep track of your HIV
medications?
It frustrates me to think that I
will have to take these HIV
medications every day for the
rest of my life
I get frustrated taking my HIV
medication because I have to
plan my life around them

57%

Privacy

Fear that others
may find out about
HIV status if
medications are
taken in public
Negative feelings
towards medications

57%

Privacy/
Interruptions
in daily life
Interruptions
in daily life

Not using a pillbox
or other reminder
device
Frustration that HIV
medications must be
taken for life

Interruptions
in daily life

Frustration in having
to plan life around
medications

57%

54%

The first three of the barriers identified by the normal dosing group, revolved
around issues dealing with privacy. The first of these barriers centered on the
problem of taking one’s medications in private. This was in fact the only barrier
that was significant when compared between the two groups. Due to the small
sample size, this finding cannot be representative of the greater HIV population.
It is interesting though that for this group of patients, the fear of taking HAART in
public is not a barrier for the renal dosed patients. A possible explanation may be
that because these patients are so ill that their kidney problems make it too
difficult to hide their health problems. If future studies show similar findings, then
future researchers may want to examine this hypothesis.
Another explanation is the fact that the renal dosed group takes their medications
less frequently making the taking of medications in private easier. It is also likely
that the patients pair this barrier with the fear of disclosing one’s HIV status. If
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patients’ immune systems are healthy, it can be easier to hide their status.
Trying to hide an illness such as renal failure can be very difficult because of the
pain that renal failure causes or the time necessary to receive dialysis
treatments, which can leave patients weakened and unable to function normally
(Johansen et al. 2003). It is possible that these factors may lead the renal
patients to rely on others for help and in turn, disclose their HIV status.
The second barrier identified by this group also centered around the factor of
privacy but dealt with the fear that the side effects of a medication could affect
one’s physical appearance. If an HIV medication causes physical side effects
such as lipodystrophy (subcutaneous fat deposits found in the body) or
lipoatrophy (the loss of subcutaneous fat), it is very hard for a patient to hide a
side effect such as this or try to explain its causes. Similar to the second barrier,
the third barrier focused on the use of a pillbox in remembering to take one’s
medications. Like a physical side effect, if a person uses a pillbox it may become
difficult to keep this hidden and take the medications in private. Another
explanation for this third barrier is that it may be difficult to use a pillbox due to
the complexities of daily life.
The lack of the presence of renal impairment for these HIV+ individuals could
explain this trend. HIV is unfortunately a highly stigmatized disease while renal
impairment on the other hand is not (Rintamaki et al. 2006). The renal dosed
individuals can disclose their renal impairment and used it as an explanation for
their health problems. They could use this to explain why they take medications
during the day and why they suffer from side effects to medications. Blaming
some of these health problems on the renal impairment can allow these
individuals to receive an understanding from others while still not disclosing their
HIV status. The patients in the normal dosed group may not have another health
condition to fall back on to blame their health problems to the public.
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The final two barriers dealt with interruptions in daily life and showed that HIV+
patients can become frustrated with the ways that their medications affect them
and their daily lives. As the effectiveness of HAART increased over time, HIV
became a chronic disease and not just a death sentence. At the same time,
there is no cure for HIV and reliance on HAART for the rest of patients’ lives can
be very frustrating. One reason why the renal dosed group did not identify these
barriers might be because those on renal dosing face a more invasive treatment
with dialysis. These patients may also view their kidney disease as a terminal
illness. Many dialysis patients suffer from depression and are more likely to think
about and commit suicide (Kurella 2005).
Because only the normal dosing group identified these barriers, these barriers
should go under further investigation to understand their true nature. It may also
be beneficial to understand why these are not barriers for the renal dosed
patients in order to help future patients who are not on renal dosing.
Health Literacy:
While conducting the study, several of the site researchers reported that by
taking part in the experiment, many of the patients became confident about their
HIV medications. The site researchers reported that in the early stages of the
study many of the patients did not know the names of their prescribed
medications and could rarely describe what they looked like. The experimenters
also noted that many of these patients did not know the difference between their
HIV medications and medications used to treat other health conditions.
This trend occurred in both the renal and normal dosing groups, and at all five of
the research sites. Added confusion existed for many of the renal dosed patients
because the computer program did not measure adherence for their renal dosed
medications. The site researchers had to leave these particular medications out
of the system’s memory when consulting the medical records. One on-site
researcher reported that one patient insisted that he continued to take the renal
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dosed medication every day. Yet the medical record and clinician’s report
showed that this was not the case.
As the study progressed fewer instances of medication discrepancies, amongst
all patients, occurred. While this result was not surprising, because the patients
grew familiar with the program over time, the field staff noted additional changes.
Over time the patients felt confident about which medications the clinicians
prescribed them. The site staff also stated that the patients appeared to display
pride in knowing information about their medications. This was conveyed by the
patients verbally telling the researchers how they felt or by the patients’ facial and
body expressions when they completed the pill-picker section.
The concept of health literacy can best explain this finding. Health literacy is “the
degree to which individuals have the capacity to obtain, process, and understand
basic health information and services needed to make appropriate health
decisions” (U.S. Department of Health and Human Services 2000). Health
literacy is important for ARV therapy adherence because the more health literate
HIV+ patients become the more likely they are to adhere to their HIV medication
regimen (Kalichman, Ramachandran, & Catz 1999).
Simply by learning the names of their medications the patients became more
informed about their health and their medications. Yet, knowing the name of a
medication is far from being considered health literate; and health literacy among
the HIV population is very limited. This is because, for the most part, the HIV
population comprises individuals that are unfortunately marginalized by society.
This includes populations such as minorities, gay men, prisoners, and IDUs.
Many HIV+ people in America are from low socio-economic levels in society and
lack the education and resources needed to learn about their disease.
The research team’s interactions with HIV+ patients supported many of these
stereotypes. The clinical sites locations were urban centers throughout the state
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and nearly all of the patients suffered from a low socio-economic status. These
patients demonstrated a low level of health literacy and appeared to know very
little about their medications at the beginning of the study.
When a provider places a patient on renal dosing, the lack of health literacy
becomes even worse. Most HIV medication regimens contain multiple
medications. Yet, very few medications cause nephrotoxicity. So when a
provider places a patient on a renal dosed regimen the nephrotoxic medication is
usually the only one not taken every day. The provider, who once convinced the
patient that he/she needed to take all his/her HIV medications every day, must
now try to explain the changes to the patient’s regimen. In a patient with low
health literacy it can be very difficult for the provider to explain the changes in the
medication regimen. It is even harder for the provider to try to explain why the
change occurred and how, although the medication damaged the kidneys,
adherence to the medication is necessary for viral suppression.
If a provider cannot convey this information in a way that the patient understands,
adherence is at jeopardy because this is one of the main factors to adherence in
the IMB model. It is also difficult for a provider to assess how much of the
information the patient understands. Due to the power relations of the patientprovider relationship and cultural differences “the absence of discourses about
rationing and the limits of therapeutic medicine reproduce old racialized tropes
and lead us into explanatory circles when it comes to trying to understand racial
health disparities” (Rousse 2010). If trust is not the foundation of the patientprovider relationship, meaningful and forthright conversations about adherence
and barriers to adherence are unlikely to occur (Bangsberg et al. 2001 and
Roberts 2000).
Renal dosing is relatively new to the HIV world. Further research on the health
literacy of renal dosed patients can yield important information to providers and
researchers. By increasing patients’ health literacy providers can convey more-
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accurate information to patients. With this information, patients can better
understand their HIV, medications, and the therapeutic strategies on. This will be
of extreme importance with the expected rise in numbers of renal dosed HIV
patients.
Conclusion:
Adherence to an ARV medication regimen is fundamental for viral suppression.
Identifying and addressing patients’ barriers to adherence can increase rates of
adherence. Renal dosing of HIV medications is still relatively new, and the
literature on adherence to HAART for this group is severely lacking. Further
investigation into understanding the management of side effects and how HIV
and renal failure act on the physical health of patients is the first step to truly
addressing the barriers these patients may face.
This thesis examined the barriers to adherence that HIV+ patients in the
LifeWindows study identified. During the study some of the patients had their
medications changed to a renal dosing regimen. The LifeWindows adherence
survey positively identified several barriers to adherence. Statistical data
analysis did not find a significant difference between the two groups as a whole
or in relation to a particular question on the survey. Further exploration, from a
qualitative perspective with the use of grounded theory, found possible trends
among the groups. This thesis discussed possible explanations for the presence
of these barriers in order to better understand these barriers. The presence of
such barriers shows that more work is necessary in order to provide information
and resources to these HIV+ patients.
Limitations:
The biggest limitation of this thesis was the small sample size of the renal dosing
population. Due to the small sample size the power was insufficient. This may
be why the data analysis did not find significance in the results. Unfortunately
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this was unavoidable since the number of patients in the clinics placed on renal
dosing was very small. In fact the providers placed about 2% of the sample on
renal dosing. This sample may be a fair representation of the HIV population in
America because only 2% of the population is on renal dosing (Hamzah & Post
2009). Yet, it is important to note that participation in the intervention arm did not
affect the barriers identified or the rates of adherence for this group.
Another limitation of this study was that the computer program could not capture
data on adherence for the renal dosed medications themselves. In order to
garner a clearer picture of these barriers, data on adherence may be necessary.
Another limitation was the dichotomizing of patient responses. To compare the
patients’ responses across questions the analysis required a standardized set of
responses. Since the survey questions possessed a wide range of responses,
the analysis required the responses to be binomial to be uniform. While this
allowed comparison between questions it also limited understanding of the
degree to which these barriers affected the patients.
The final limitation in this thesis was that the survey was a structured interview in
which patients had a limited number of responses to choose from. This limitation
did not affect the overall LifeWindows study, but it did affect the data captured on
those patients whose providers switched them to a renal dosing regimen. Since
there is very little known about renal dosing, obtaining an emic perspective would
allow the renal dosed patients to explain more about their experiences with their
medications.
Future Recommendations:
The analysis found 14 barriers to adherence that more than half of the population
of either the renal dosed group or normal dosed group identified. Future
research should test these barriers against a larger population of renal dosed
patients. A larger population can accurately gauge whether or not these barriers
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are significant. Also, a larger population may provide results that researchers
could generalize to the larger HIV population.
While a larger population size of renal dosed patients is necessary, both groups
identified four barriers. These barriers are of major concern because they
impacted both groups. Therefore researchers should study these barriers right
away. The barriers that only the normal dosed patients identified should also go
under further investigation in relation to the renal dosed patients. It may prove
useful to understand why certain barriers are not problematic for those patients
on renal dosing.
It would be very instructive to conduct semi-structured interviews in future
studies. These interviews could examine the questions on the survey in more
depth and allow future researchers to obtain a more in-depth, emic perspective
from the patients. The following examples provide reasons why an in-depth emic
perspective is necessary to understand the illness narratives of the patients:
1) All patients identified the fear of side effects as a possible barrier to
adherence. The normal group did not have a problem managing the side
effects of their medications while the renal group did. This does not tell us
if the normal dosed patients could manage their side effects effectively or
if they did not experience side effects at all.
2) The renal group identified physical health problems as a barrier to
adherence. While this barrier may exist for this population, the data do not
tell us if this is related to the problems these patients have with their
kidney failure or not.
3) Both groups identified difficulty in taking their medications when they did
not feel emotionally well. According to the survey, not feeling emotionally
well included: depression, sadness, anger, and stress. While these are all
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negative emotions, there are differences between them. It may be
necessary to determine which emotion patients experience and what
caused the patients to feel that way. Treatment and coping for each of
these emotions may be different. An argument could also be made that
since most patients in the study did not feel emotionally well, all patients
may need better mental health therapy.
As previously stated, the research conducted on adherence for HIV+ patients
placed on renal dosing ARV medication regimens is scarce. This thesis is the
starting point of adherence research for this population and can help guide future
research. Researchers should use these results to further investigate this
population to determine if these trends are unique to this study or are
representative of the greater population. Since the rates of renal dosing of HIV
medications will most likely increase in the coming years, it is important to
understand the barriers to adherence for this population while its size remains
small. By doing so, we can develop interventions and strategies to combat
noncompliance before the population size increases. Thus, more research on
this topic is necessary.
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Appendix
Table 7: LifeWindows Demographic Survey Questions
Item
1

Question
What is your
racial/ethnic
background?
(Please click all that
apply.)

Response

! Hispanic American or Latino(a)

! American Indian or
Alaskan Native
! Native Hawaiian or Other
Pacific Islander

! White (not Hispanic)

! Other

! African American or Black

! Asian American
2

Are you…? (Please
click one.)

! Transgender
! Male
! Female

3

4

5

What is the highest
level of education
you have
completed? (Please
click one.)
What is your family
income per year?
(Please click one. If
you don't know,
please make your
best guess.)
How many people
are supported by this
income, including
yourself? (Please
click one.)

! Some high school or less

! College degree (BA, BS)

! High school diploma or GED
! Some college

! Some graduate school
! Graduate degree (MA, JD,
PhD, MD, etc)

! Under $5,000

! $30,001 to $50,000

! $5,000 to $10,000

! $50,001 to $75,000

! $10,001 to $20,000

! Over $75,000

! $20,001 to $30,000
! 1 (myself)
!2
!3
!4
!5

6

Where are you living
right now? (Please
click one.)

! Intersexed

!6
!7
!8
!9
! 10 or more

! Living on the street.
! Living in an abandoned building.
! Living in a homeless shelter.
! Living in a halfway house, assisted living residence, or rehabilitation program.
! Living in a friend's or family member's house or apartment.
! Living in a house, condominium, apartment or room that you rent or own.

7

8

9
10

What is your sexual
orientation? (Please
click one.)
How do you think
you got HIV?
(Please click all that
apply. If you are
unsure, please make
your best guess.)
In what year were
you diagnosed with
HIV? (Please click
one.)
How many children
do you care for in
your home? (Please
click one.)

! Gay or lesbian

! Bisexual

! Straight or heterosexual

! Unsure / don’t know

! Having sex with a man who had HIV

! Blood transfusion

! Having sex with a woman who had HIV

! Got it at birth

! Sharing needles or works

! Don't know

1980-2006
! 0 (no children)

!4

!1

!5

!2

! 6 or more children

!3
11

!

What statement best
describes your
employment status?
(Please click one.)

! Currently unemployed

! On disability or sick leave

! Employed part-time

! Retired

! Employed full-time

'$!

Table 8: LifeWindows Barriers to Adherence Survey Questions
Question

Barrier Identified

Are you now taking a break from your HIV
medications without having talked to your
healthcare provider about it? (Please click one.)

o

Yes

o

No

Not adhering to ARV therapy

As long as I am feeling healthy, missing my HIV
medications from time to time is OK.

o

I strongly disagree

o

I somewhat disagree

Lack of knowledge about HIV and ARV
therapy

o
o

I neither agree nor
disagree
I somewhat agree

o

I strongly agree

o

Not at all

o

Very little

o

Somewhat

o

Quite a lot

o
o

Could not do daily
activities
Not at all

o

Very little

o

Somewhat

o

Quite a lot

o
o

Could not do physical
activities
Not at all

o

Quite a lot

o

Very little

o

Somewhat

o
o

Could not do social
activities
None at all

o

A little bit

o

Some

o

Quite a lot

o
o

Could not do daily
work
Very much

o

Quite a lot

o

Some

o

A little bit

o

None

During the past 4 weeks, how much did personal or
emotional problems keep you from doing your
usual work, school or other daily activities?

During the past 4 weeks, how much did physical
health problems limit your usual physical activities
(such as walking or climbing stairs)?

During the past 4 weeks, how much did your
physical health or emotional problems limit your
usual social activities with family or friends?

During the past 4 weeks, how much difficulty did
you have doing your daily work, both at home and
away from home, because of your physical health?

During the past 4 weeks, how much energy did you
have?

!

Response

Not feeling good emotionally

Physical health problems limit ability to
perform daily functions

Difficulty in engaging in social activities
due to health problems

Difficulty in performance of daily work
due to physical health problems

Lack of energy

'%!

During the past 4 weeks, how much have you been
bothered by emotional problems (such as feeling
anxious, depressed, or irritable)?

How hard is it for you to pay for your HIV
medications each month? (Please click one.)

How hard or easy is it for you to get the support you
need from others for taking your HIV medications
(for example, from friends, family, doctor, or
pharmacist)?

How hard or easy is it for you to get your HIV
medication refills on time?

How hard or easy is it for you to make your HIV
medications part of your daily life?

How hard or easy is it for you to manage the side
effects of your HIV medications?

!

o

Not at all

o

Slightly

o

Moderately

o

Quite a lot

o
o

Extremely
Very hard

o

Hard

o

Neither hard nor easy

o

Easy

o

Very easy

o
o

I don't pay anything
Very Hard

o

Hard

o

Sometimes hard,
sometimes easy

o

Easy

o

Very Easy

o

Very Hard

o

Hard

o

Sometimes hard,
sometimes easy

o

Easy

o

Very Easy

o

Very Hard

o

Hard

o

Sometimes hard,
sometimes easy

o

Easy

o

Very Easy

o

Very Hard

o

Hard

o

Sometimes hard,
sometimes easy

o

Easy

o

Very Easy

Not feeling good emotionally

Financial Issues

Lack of social support structures

Difficulty in refilling prescriptions

Difficulty in making medications a part
of daily life

Difficulty in managing the side effects to
medications
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How hard or easy is it for you to remember to take
your HIV medications?

How hard or easy is it for you to stay informed
about HIV treatment?

How hard or easy is it for you to take your HIV
medications because the pills are hard to swallow,
taste bad, or make you sick to your stomach?

How hard or easy is it for you to take your HIV
medications when you are wrapped up in what you
are doing?

How hard or easy is it for you to take your HIV
medications when you do not feel good emotionally
(for example, when you are depressed, sad, angry,
or stressed out)?

How hard or easy is it for you to take your HIV
medications when you do NOT feel good
physically?
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o

Very Hard

o

Hard

o

Sometimes hard,
sometimes easy

o

Easy

o

Very Easy

o

Very Hard

o

Hard

o

Sometimes hard,
sometimes easy

o

Easy

o

Very Easy

o

Very Hard

o

Hard

o

Sometimes hard,
sometimes easy

o

Easy

o

Very Easy

o

Very Hard

o

Hard

o

Sometimes hard,
sometimes easy

o

Easy

o

Very Easy

o

Very Hard

o

Hard

o

Sometimes hard,
sometimes easy

o

Easy

o

Very Easy

o

Very Hard

o

Hard

o

Sometimes hard,
sometimes easy

o

Easy

o

Very Easy

Forgetting to take medications

Difficulty in gathering information

Problem taking pills

Forgetting to take medications

Not feeling good emotionally

Difficulty in taking medications when not
feeling good physically
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How hard or easy is it for you to take your HIV
medications when you feel good physically and
don’t have any symptoms of your HIV disease?

How hard or easy is it for you to take your HIV
medications when your usual routine changes (for
example, when you travel or when you go out with
your friends)?

How hard or easy is it for you to talk to your
healthcare provider about your HIV medications?

How much bodily pain have you had during the
past 4 weeks?

How often do you use a pillbox to help keep track of
your HIV medications? (Please click one.)

I am worried that other people might realize that I
am HIV+ if they see me taking my HIV medications.
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o

Very Hard

o

Hard

o

Sometimes hard,
sometimes easy

o

Easy

o

Very Easy

o

Very Hard

o

Hard

o

Sometimes hard,
sometimes easy

o

Easy

o

Very Easy

o

Very Hard

o

Hard

o

Sometimes hard,
sometimes easy

o

Easy

o

Very Easy

o

None

o

Very mild

o

Mild

o

Moderate

o

Severe

o

Very severe

o

Never

o

Once in a while

o

Half the time

o

Usually

o

Always

o

I strongly disagree

o

I somewhat disagree

o
o

I neither agree nor
disagree
I somewhat agree

o

I strongly agree

Lack of knowledge about HIV and ARV
therapy

Changes in one’s daily routine

Poor patient-provider communication

Experiencing and dealing bodily pain

Not using a pillbox or other reminder
device

Fear that others may find out about HIV
status if medications are taken in public
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I am worried that the HIV medications I have been
prescribed will hurt my health.

I believe that if I take my HIV medications as
prescribed, I will live longer.

I don’t like taking my HIV medications because they
remind me that I am HIV+.

I feel that my healthcare provider takes my needs
into account when making recommendations about
which HIV medications to take.

I get frustrated taking my HIV medications because
I have to plan my life around them.

I know how each of my current HIV medications is
supposed to be taken (for example whether or not
my current medications can be taken with food,
herbal supplements, or other prescription
medications).

I know how my HIV medications interact with
alcohol and street drugs.

I know what the possible side effects of each of my
HIV medications are.
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o

I strongly disagree

o

I somewhat disagree

o
o

I neither agree nor
disagree
I somewhat agree

o

I strongly agree

o

I strongly disagree

o

I somewhat disagree

o
o

I neither agree nor
disagree
I somewhat agree

o

I strongly agree

o

I strongly disagree

o

I somewhat disagree

o
o

I neither agree nor
disagree
I somewhat agree

o

I strongly agree

o

I strongly disagree

o

I somewhat disagree

o
o

I neither agree nor
disagree
I somewhat agree

o

I strongly agree

o

I strongly disagree

o

I somewhat disagree

o
o

I neither agree nor
disagree
I somewhat agree

o
o

I strongly agree
I strongly disagree

o

I somewhat disagree

o
o

I neither agree nor
disagree
I somewhat agree

o
o

I strongly agree
I strongly disagree

o

I somewhat disagree

o
o

I neither agree nor
disagree
I somewhat agree

o
o

I strongly agree
I strongly disagree

o

I somewhat disagree

o
o

I neither agree nor
disagree
I somewhat agree

o

I strongly agree

Fear of a medications’ side effects

Lack of knowledge about HIV and ARV
therapy

Negative emotions towards HIV and/or
ARV therapy

Poor patient-provider communication

Frustration in having to plan life around
medications

Lack of knowledge about HIV and ARV
therapy

Substance abuse: drugs and/or alcohol

Lack of knowledge about ARV therapy
in relation to side effects
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I know what to do if I miss a dose of any of my HIV
medications (for example, whether or not to take
the pill(s) later).

I understand how each of my HIV medications
works in my body to fight HIV.

If I don’t take my HIV medications as prescribed,
these kinds of medications may not work for me in
the future.

It frustrates me to think that I will have to take these
HIV medications every day for the rest of my life.

It upsets me that the HIV medications I have been
prescribed can affect the way I look.

It upsets me that the HIV medications I have been
prescribed can cause side effects.

Most people who are important to me who know I’m
HIV positive support me in taking my HIV
medications.
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o

I strongly disagree

o

I somewhat disagree

o
o

I neither agree nor
disagree
I somewhat agree

o

I strongly agree

o

I strongly disagree

o

I somewhat disagree

o
o

I neither agree nor
disagree
I somewhat agree

o

I strongly agree

o

I strongly disagree

o

I somewhat disagree

o
o

I neither agree nor
disagree
I somewhat agree

o

I strongly agree

o

I strongly disagree

o

I somewhat disagree

o
o

I neither agree nor
disagree
I somewhat agree

o

I strongly agree

o

I strongly disagree

o

I somewhat disagree

o
o

I neither agree nor
disagree
I somewhat agree

o

I strongly agree

o

I strongly disagree

o

I somewhat disagree

o
o

I neither agree nor
disagree
I somewhat agree

o

I strongly agree

o

I strongly disagree

o

I somewhat disagree

o
o

I neither agree nor
disagree
I somewhat agree

o

I strongly agree

o

No one that I care
about knows I am
positive

Lack of knowledge about ARV therapy
in relation of missing a dose

Lack of knowledge about HIV and ARV
therapy

Lack of knowledge about HIV and ARV
therapy

Frustration that HIV medications must
be taken every day for life

Negative feelings towards medications
because side effects can affect the
physical appearance

Fear of a medication’s side effects

Lack of social support structures
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My healthcare provider doesn’t give me enough
support when it comes to taking my medications as
prescribed.

Overall, how would you rate your health during the
past 4 weeks?

Skipping a few of my HIV medications from time to
time would not really hurt my health.

There are times when it is hard for me to take my
HIV medications when I drink alcohol or use street
drugs.

When was the last time you injected or “shot up”
street drugs (such as heroin or cocaine)?
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o

I strongly disagree

o

I somewhat disagree

o
o

I neither agree nor
disagree
I somewhat agree

o

I strongly agree

o

Excellent

o

Very good

o

Good

o

Fair

o

Poor

o
o

Very poor
I strongly disagree

o

I somewhat disagree

o
o

I neither agree nor
disagree
I somewhat agree

o
o

I strongly agree
I strongly disagree

o

I somewhat disagree

o
o

I neither agree nor
disagree
I somewhat agree

o

I strongly agree

o
o

Not Applicable (I don’t
drink alcohol or use
street drugs)
Never

o

Over a month ago

o

In the past month

Lack of social support structures

Being in a state of poor health

Lack of knowledge about HIV and ARV
therapy

Substance abuse: drugs/and or alcohol

Substance abuse: drugs and/or alcohol
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Table 9: LifeWindows Intervention Modules
Intervention Module

Battle for Health

Bill the Pill

Celebrate Success

Doc Talk

Felicia the Pharmacist

Focus on the Fight

Helping Hand

HIV, Drugs, and Alcohol

Journey through the Bloodstream

Information Station

Learning from a Missed Dose

!

Description
A video game in which patients battle
infections, take ARV on-time to fight HIV, and
use tools (e.g., pillboxes, alarms) to ensure
that ARV are taken, even in challenging
situations.
An animated character presents strategies for
taking pills that are hard to swallow or taste
bad, taking large numbers of pills, and taking
medications that make one feel nauseous.
Offered to patients with perfect adherence.
Patients create a personalized reward
certificate and then learn about maintaining
adherence over time.
A video-based intervention in which patients
can “ask” HIV doctors about a number of HIVrelated issues, including HIV treatment, side
effects, and resistance.
A video-based intervention in which patients
are able to “ask” a pharmacist questions about
their HIV prescriptions.
Involves an activity that helps patients
visualize the therapeutic effects of HIV
medications.
By playing the role of an adherence counselor
to help other PLWHA overcome their barriers
to adherence, patients learn strategies for
dealing with their own adherence-related
issues.
Discusses the effects of street drugs and
alcohol on the body, street drug and alcohol
interactions with ARV, and tips for staying
healthy when using street drugs and/or
alcohol.
An animated sequence that uses simple
representations to explain T-Cells, CD-4
count, HIV, viral load, how ARVs help fight
HIV in the body, and drug resistance.
Describes services locally available for
PLWHA, including counseling and support
groups, mental health services, substance
abuse treatment, and housing assistance.
Patients are taught to assess the
circumstances surrounding a missed dose and
learn to identify, understand, and overcome
their barriers to adherence.
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Lipodystrophy

Match-Up

Med Minders

The Misadventures of Skip Sisdose

My Meds

Patient-Provider Communication

Positive Voices

Side Effects Solutions

Stress Management

Includes unscripted video accounts of four
different personal experiences with
lipodystrophy. The intervention also discusses
possible causes and treatment options.
Patients create and print a personalized
calendar on which ARV dose times are
matched-up with recurring activities.
Describes tools and devices that can help
patients take their medications on time, every
time.
Uses humorous animation to provide tips for
fitting ARV into one’s daily life, taking ARV
when one’s routine changes, and taking ARV
when others are around.
A comprehensive resource that provides
information about HIV medications, including
dosing, side effects, drug interactions, and
dietary restrictions for each medication.
Addresses communication skills, with a focus
on the doctor-patient relationship. Skills are
presented through a series of video-based
doctor-patient interactions.
A video-based intervention in which
participants can “ask” other PLWHA about
their experiences with HIV and HIV
medications.
Presents detailed information regarding side
effects associated with HIV medications, and
provides participants with tips and strategies
for managing their side effects.
Patients learn about the nature of stress,
particularly as it relates to living with HIV and
ARV adherence. A variety of stress-reduction
activities and strategies are provided.

Information courtesy of LifeWindows Project Team 2006: Draft of results.
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Table 10: Listing of Strategies Addressed in LifeWindows
Learn more about your HIV medications, like how they’re supposed to be taken or
what to do if you miss a dose.
Learn how skipping your HIV medications from time to time can keep them from
working for you and hurt your health.
Learn more about how your HIV medications work in your body.
Learn about the side effects of your HIV medications and ways to deal with them.
Learn about ways to hide your HIV meds and to take them in private.
Learn how to make your HIV medications part of your daily life and feel less
frustrated about them.
Learn ways to feel better about your HIV and your HIV medications.
Work on ways to talk more effectively with your healthcare provider to get them to
better understand your HIV medication needs.
Learn how taking your HIV medications as prescribed can help you to live longer.
Learn more about how HIV medications affect your health.
Learn how HIV medications can affect the way you look and what you can do about
it.
Learn ways to get more support from others (such as friends, family, healthcare
provider, pharmacist, etc.) for taking your HIV medications.
Learn how to get the information you want about HIV treatment.
Learn ways to get your medication refills on time.
Learn things you can do to help you remember to take your HIV medications, even
when you’re wrapped up in what you’re doing or your routine changes.
Learn how to take pills that are too big, taste bad, or make you feel sick.
Learn about taking HIV medications when using alcohol or street drugs.
Learn how to deal with negative emotions and taking your HIV medications.
Learn why you need to take your HIV medications as prescribed, even when you’re
feeling healthy.
Learn ways to take your HIV medications when you’re not feeling well.
Learn how to identify what gets in the way of you taking your medications.
Reward yourself for taking all of your HIV medications.
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Table 11: Questions, Strategies, and Interventions used in LifeWindows
Question
Are you now taking a break from
your HIV medications without
having talked to your healthcare
provider about it? (Please click
one.)
As long as I am feeling healthy,
missing my HIV medications from
time to time is OK.
During the past 4 weeks, how
much did personal or emotional
problems keep you from doing
your usual work, school or other
daily activities?
During the past 4 weeks, how
much did physical health
problems limit your usual physical
activities (such as walking or
climbing stairs)?
During the past 4 weeks, how
much did your physical health or
emotional problems limit your
usual social activities with family
or friends?
During the past 4 weeks, how
much difficulty did you have doing
your daily work, both at home and
away from home, because of
your physical health?
During the past 4 weeks, how
much energy did you have?
During the past 4 weeks, how
much have you been bothered by
emotional problems (such as
feeling anxious, depressed, or
irritable)?

Strategy

Intervention

Was not linked to a strategy
Learn how skipping your HIV
medications from time to time can
keep them from working for you
and hurt your health.

Not Applicable

Was not linked to a strategy

Not Applicable

Was not linked to a strategy

Not Applicable

Was not linked to a strategy

Not Applicable

Was not linked to a strategy

Not Applicable

Was not linked to a strategy

Not Applicable

Was not linked to a strategy

Not Applicable

Was not linked to a strategy

Not Applicable

Journey Through the
Bloodstream, Doc
Talk, Positive Voices

How hard is it for you to pay for
your HIV medications each
month? (Please click one.)
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How hard or easy is it for you to
get the support you need from
others for taking your HIV
medications (for example, from
friends, family, doctor, or
pharmacist)?
How hard or easy is it for you to
get your HIV medication refills on
time?

Learn ways to get your medication
refills on time.

How hard or easy is it for you to
make your HIV medications part
of your daily life?

Learn how to make your HIV
medications part of your daily life
and feel less frustrated about
them.

How hard or easy is it for you to
manage the side effects of your
HIV medications?

Learn about the side effects of
your HIV medications and ways to
deal with them.

How hard or easy is it for you to
remember to take your HIV
medications?

Learn things you can do to help
you remember to take your HIV
medications, even when you’re
wrapped up in what you’re doing
or your routine changes.

How hard or easy is it for you to
stay informed about HIV
treatment?
How hard or easy is it for you to
take your HIV medications
because the pills are hard to
swallow, taste bad, or make you
sick to your stomach?
How hard or easy is it for you to
take your HIV medications when
you are wrapped up in what you
are doing?
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Learn ways to get more support
from others (such as friends,
family, healthcare provider,
pharmacist, etc.) for taking your
HIV medications.

Learn how to get the information
you want about HIV treatment.
Learn how to take pills that are too
big, taste bad, or make you feel
sick.
Learn things you can do to help
you remember to take your HIV
medications, even when you’re
wrapped up in what you’re doing
or your routine changes.

Positive Voices. Doc
Talk, Information
Station, PatientProvider
Communication,
Felicia the
Pharmacist, Helping
Hand
Felicia the
Pharmacist. Helping
Hand
Match-Up, Positive
Voices, Doc Talk,
Focus on the Fight,
Stress Management,
Med Minders,
Misadventures of
Skip Sisdose, Battle
for Health
Side Effects
Solutions, My Meds,
Felicia the
Pharmacist, Doc
Talk, Positive Voices,
Lipodystrophy,
Helping Hand
Med Minders, MatchUp, Battle for Health,
Positive Voices,
Helping Hand,
Misadventures of
Skip Sisdose
Patient-Provider
Communication, Doc
Talk, Felicia the
Pharmacist,
Information Station
Bill the Pill, Side
Effect Solutions, Doc
Talk, Felicia the
Pharmacist, Battle for
Health
Med Minders, MatchUp, Battle for Health,
Positive Voices,
Helping Hand,
Misadventures of
Skip Sisdose
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How hard or easy is it for you to
take your HIV medications when
you do not feel good emotionally
(for example, when you are
depressed, sad, angry, or
stressed out)?

How hard or easy is it for you to
take your HIV medications when
you do NOT feel good physically?
How hard or easy is it for you to
take your HIV medications when
you feel good physically and don’t
have any symptoms of your HIV
disease?
How hard or easy is it for you to
take your HIV medications when
your usual routine changes (for
example, when you travel or
when you go out with your
friends)?
How hard or easy is it for you to
talk to your healthcare provider
about your HIV medications?
How much bodily pain have you
had during the past 4 weeks?
How often do you use a pillbox to
help keep track of your HIV
medications? (Please click one.)
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Learn how to deal with negative
emotions and taking your HIV
medications.

Learn ways to take your HIV
medications when you’re not
feeling well.
Learn why you need to take your
HIV medications as prescribed,
even when you’re feeling healthy.
Learn things you can do to help
you remember to take your HIV
medications, even when you’re
wrapped up in what you’re doing
or your routine changes.
Work on ways to talk more
effectively with your healthcare
provider to get them to better
understand your HIV medication
needs.

Stress Management,
Positive Voices,
Information Station,
Helping Hand
Side Effects
Solutions, Bill the Pill,
Doc Talk, Positive
Voices, Helping
Hand, Focus on the
Fight
Positive Voices, Doc
Talk, Journey
Through the
Bloodstream
Med Minders, MatchUp, Battle for Health,
Positive Voices,
Helping Hand,
Misadventures of
Skip Sisdose
Patient-Provider
Communication, Doc
Talk, Helping Hand

Was not linked to a strategy

Not Applicable

Was not linked to a strategy

Not Applicable
Med Minders,
Misadventures of
Skip Sisdose, Felicia
the Pharmacist, Doc
Talk, Positive Voices,
Battle for Health,
Helping Hand
Side Effects
Solutions, Doc Talk,
Positive Voices, My
Meds, Lipodystrophy,
Journey Through the
Bloodstream, Helping
Hand

I am worried that other people
might realize that I am HIV+ if
they see me taking my HIV
medications.

Learn about ways to hide your HIV
meds and to take them in private.

I am worried that the HIV
medications I have been
prescribed will hurt my health.

Learn more about how HIV
medications affect your health.
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I believe that if I take my HIV
medications as prescribed, I will
live longer.

Learn how taking your HIV
medications as prescribed can
help you to live longer.

I don’t like taking my HIV
medications because they remind
me that I am HIV+.
I feel that my healthcare provider
takes my needs into account
when making recommendations
about which HIV medications to
take.

Learn ways to feel better about
your HIV and your HIV
medications.
Work on ways to talk more
effectively with your healthcare
provider to get them to better
understand your HIV medication
needs.

I get frustrated taking my HIV
medications because I have to
plan my life around them.
I know how each of my current
HIV medications is supposed to
be taken (for example whether or
not my current medications can
be taken with food, herbal
supplements, or other
prescription medications).
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Learn how to make your HIV
medications part of your daily life
and feel less frustrated about
them.

Learn more about your HIV
medications, like how they’re
supposed to be taken or what to
do if you miss a dose.

Journey Through the
Bloodstream, Doc
Talk, Positive Voices,
Battle for Health,
Helping Hand
Focus on the Fight,
Positive Voices, Doc
Talk, Stress
Management,
Information Station,
Helping Hand
Patient-Provider
Communication, Doc
Talk, Helping Hand
Match-Up, Positive
Voices, Doc Talk,
Focus on the Fight,
Stress Management,
Med Minders,
Misadventures of
Skip Sisdose, Battle
for Health

I know how my HIV medications
interact with alcohol and street
drugs.

Learn about taking HIV
medications when using alcohol or
street drugs.

I know what the possible side
effects of each of my HIV
medications are.

Learn about the side effects of
your HIV medications and ways to
deal with them.

Felicia the
Pharmacist, My Meds
HIV, Drugs, and
Alcohol, My Meds,
Doc Talk, Positive
Voices
Side Effects
Solutions, My Meds,
Felicia the
Pharmacist, Doc
Talk, Positive Voices,
Lipodystrophy,
Helping Hand

I know what to do if I miss a dose
of any of my HIV medications (for
example, whether or not to take
the pill(s) later).

Learn more about your HIV
medications, like how they’re
supposed to be taken or what to
do if you miss a dose.

Felicia the
Pharmacist, My Meds

I understand how each of my HIV
medications works in my body to
fight HIV.

Learn more about how your HIV
medications work in your body.

Journey Through the
Bloodstream, Doc
Talk, Positive Voices
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If I don’t take my HIV medications
as prescribed, these kinds of
medications may not work for me
in the future.
It frustrates me to think that I will
have to take these HIV
medications every day for the rest
of my life.
It upsets me that the HIV
medications I have been
prescribed can affect the way I
look.

Learn ways to feel better about
your HIV and your HIV
medications.
Learn how HIV medications can
affect the way you look and what
you can do about it.

It upsets me that the HIV
medications I have been
prescribed can cause side
effects.

Learn about the side effects of
your HIV medications and ways to
deal with them.

Most people who are important to
me who know I’m HIV positive
support me in taking my HIV
medications.

Learn ways to get more support
from others (such as friends,
family, healthcare provider,
pharmacist, etc.) for taking your
HIV medications.

My healthcare provider doesn’t
give me enough support when it
comes to taking my medications
as prescribed.
Overall, how would you rate your
health during the past 4 weeks?
Skipping a few of my HIV
medications from time to time
would not really hurt my health.
There are times when it is hard
for me to take my HIV
medications when I drink alcohol
or use street drugs.
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Learn how skipping your HIV
medications from time to time can
keep them from working for you
and hurt your health.

Learn ways to get more support
from others (such as friends,
family, healthcare provider,
pharmacist, etc.) for taking your
HIV medications.
Was not linked to a strategy
Learn how skipping your HIV
medications from time to time can
keep them from working for you
and hurt your health.
Learn about taking HIV
medications when using alcohol or
street drugs.

Journey Through the
Bloodstream, Doc
Talk, Positive Voices
Focus on the Fight,
Positive Voices, Doc
Talk, Stress
Management,
Information Station,
Helping Hand
Lipodystrophy. Doc
Talk, Side Effect
Solutions
Side Effects
Solutions, My Meds,
Felicia the
Pharmacist, Doc
Talk, Positive Voices,
Lipodystrophy,
Helping Hand
Positive Voices. Doc
Talk, Information
Station, PatientProvider
Communication,
Felicia the
Pharmacist, Helping
Hand
Positive Voices. Doc
Talk, Information
Station, PatientProvider
Communication,
Felicia the
Pharmacist, Helping
Hand
Not Applicable
Journey Through the
Bloodstream, Doc
Talk, Positive Voices
HIV, Drugs, and
Alcohol, My Meds,
Doc Talk, Positive
Voices
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When was the last time you
injected or “shot up” street drugs
(such as heroin or cocaine)?

Was not linked to a strategy

During the Self-Report: if the
Patient had Less than 100%
adherence
During the Self-Report: If the
Patient had 100% adherent

Learn how to identify what gets in
the way of you taking your
medications.
Reward yourself for taking all of
your HIV medications.

Not Applicable

Learning From a
Missed Dose
Celebrate Success
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Table 12: Barriers Addressed in LifeWindows
Being in a state of poor health
Changes in one’s daily routine
Difficulty in engaging in social activities due to health problems
Difficulty in gathering information
difficulty in identifying barriers to adherence
Difficulty in making medications a part of daily life
Difficulty in managing the side effects to medications
Difficulty in performance of daily work due to physical health problems
Difficulty in refilling prescriptions
Difficulty in taking medications when not feeling good physically
Experiencing and dealing bodily pain
Experiencing bodily pain
Fear of a medications’ side effects
Fear of side effects that affect physical appearance
Fear that others may find out about HIV status if medications are taken in public
Financial Issues
Forgetting to take medications
Frustration about having to take medications
Frustration in having to plan life around medications
Frustration that HIV medications must be taken every day for life
Issues dealing with privacy and disclosure of HIV status
Lack of energy
Lack of knowledge about ARV therapy in relation of missing a dose
Lack of knowledge about ARV therapy in relation to side effects
Lack of knowledge about HIV and ARV therapy
Lack of social support structures
Negative emotions towards HIV and/or ARV therapy
Negative feelings towards medications because side effects can affect the
physical appearance
Not acknowledging one's accomplishments
Not adhering to ARV therapy
Not feeling good emotionally
Not feeling good emotionally
Not using a pillbox or other reminder device
Physical health problems limit ability to perform daily functions
Physical health problems limit ability to take medications
Poor patient-provider communication
Problem taking pills
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